正在招募
Phase 2
生物制剂药物手术/操作
clinicaltrials.gov
NCT06649812
海外临床试验导航
淋巴瘤
帮助用户按 DLBCL、滤泡性淋巴瘤、霍奇金淋巴瘤、CAR-T、双抗等方向检索海外公开临床试验。
Synced trials
当前同步到的治疗类试验
以下记录来自公开临床试验数据库，已按招募状态、治疗目的、干预类型和癌症相关性做初步过滤。本站不判断患者是否符合入组条件，请以官方页面、医生和研究团队意见为准。
招募状态和入组条件可能随时变化。请以官方页面、医院和研究机构信息为准，并带给主治医生或肿瘤科医生讨论。
状态
全部
试验阶段
全部
治疗类型
全部
国家/地区
全部
正在招募
Phase 3
药物
clinicaltrials.gov
NCT05018520
The Safety and Effectiveness of 4R-CHOP+4R vs 6R-CHOP+2R in Newly Diagnosed Patients With DLBCL in Low Risk
正在招募
EARLY / Phase 1
生物制剂
clinicaltrials.gov
NCT07548697
A Clinical Study Exploring the Safety, Efficacy and Metabolic Kinetics of CT1182 Injection in Patients With Relapsed / Refractory Non Hodgkin Lymphoma
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05905328
Study of CTO1681 for the Prevention and Treatment of CRS in DLBCL Patients Receiving CAR T-Cell Therapy
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06667687
Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma
正在招募
Phase 1, Phase 2
生物制剂药物
clinicaltrials.gov
NCT04836507
Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia Patients
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06768905
IOMAB-CAR-T Followed by CAR-T Cell Therapy in R/R DLBCL
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06517511
Selinexor in Combination With R-CHOP as the First-line Therapy for TP53-mutated DLBCL Patients (Smart Trial)
即将招募
Phase 1
药物
clinicaltrials.gov
NCT07638982
Axatilimab + CAR-T for High-Risk Lymphoma
正在招募
阶段未标明
药物
clinicaltrials.gov
NCT07072208
Pomalidomide, Rituximab and Orelabrutinib Combined With Polatuzumab Vedotin in the Treatment of Newly Diagnosed Elderly Patients With DLBCL
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06091865
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06901999
Methotrexate or Thiotepa Combined With R-CHOP and Orelabrutinib in CNSL Patients
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05257018
R-CDOP Combined With Intrathecal Methotrexate for DLBCL Patients With High-risk of CNS Relapse
正在招募
Phase 2
器械药物基因治疗
clinicaltrials.gov
NCT06500273
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
正在招募
Phase 1, Phase 2
生物制剂
clinicaltrials.gov
NCT07410494
Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06778902
AZA Combined with R-GemOx for Elderly DLBCL Patients
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07012980
Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL
即将招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07035379
A Phase I/II Study of TRS005 in Combination With Cyclophosphamide, Doxorubicin, and Prednisone（T-CHP） in Previously Untreated Patients With CD20-positive DLBCL
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06806033
A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06890585
Zanubrutinib, Chidamide, and Rituximab Induction With or Without CHOP Versus R-CHOP in Newly Diagnosed Double-Expressor DLBCL
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06062641
Selinexor Combined With R-GDP Regimen for TP53-altered R/R DLBCL
即将招募
Phase 2
药物
clinicaltrials.gov
NCT05596097
Zanubrutinib in Maintenance Therapy of DLBCL Patients With Initial Remission
即将招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07398638
Lisatoclax Plus R-CHOP or Pola-R-CHP in Untreated DLBCL: A Phase Ib/II Study
即将招募
Phase 1
药物
clinicaltrials.gov
NCT07583771
A Phase Ⅰ Study of CS08399 in Participants With MTAP-deleted Solid Tumors and Lymphoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07189065
A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06743945
POLA-R-CHP in the First-line Treatment of Transformed DLBCL
正在招募
EARLY / Phase 1
药物
clinicaltrials.gov
NCT07162012
Safety and Efficacy of Anti-EBV Autologous TCR-T Cell Injection in Relapsed/Refractory EBV-Positive Lymphoma
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06886139
A Phase 2 Study of TRS005 in Patients With CD20-positive R/R DLBCL.
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06750991
CD-RCHOP in ND DLBCL With a Combination of TP53 Mutation and Del(17p)
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07507318
Chidamide Maintenance for MRD-Positive Double-Expressor DLBCL in First Complete Remission
正在招募
Phase 1
生物制剂药物手术/操作
clinicaltrials.gov
NCT06015880
Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
即将招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07503353
A Phase 1/2 Study of T-cell Expressing a Novel CD19 Chimeric-Antigen Receptor (SHB-02-CD19) in Patients With CD19-expressing B-cell Malignancies
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06918912
Study of Loncastuximab Tesirine in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) or High-Grade B-Cell Lymphoma (HGBCL) Following CAR-T Therapy Failure
正在招募
Phase 2
药物
clinicaltrials.gov
NCT03758989
A Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma
即将招募
EARLY / Phase 1
药物
clinicaltrials.gov
NCT07168291
Novel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Relapsed or Refractory B-cell Lymphoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06846463
Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06803693
Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06158399
AZA Combined With RCHOP in P53-mutated DLBCL.
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06921044
A Study of R-mini-MCOP in the Treatment of Elderly, Previously Untreated DLBCL
正在招募
Phase 1
药物基因治疗
clinicaltrials.gov
NCT06528301
A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07034508
A Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patients With IPI 0-1
即将招募
阶段未标明
药物
clinicaltrials.gov
NCT07476378
A Study to Evaluate MTM-H-001 Injection in Adult Participants With Relapsed or Refractory B-cell Malignancies
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT04432714
Lenalidomide in Combination With R-DA-EPOCH in Patients With Untreated DLBCL With MYC Rearrangement
正在招募
Phase 3
生物制剂
clinicaltrials.gov
NCT07188558
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07231250
Glofitamab Plus Polatuzumab Vedotin and Zuberitamab in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07001540
Evaluation of the Efficacy and Safety of Polatuzumab Vedotin Combined With Rituximab, Gemcitabine, and Oxaliplatin (Pola-R-GemOx) as Salvage Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients Ineligible for Autologous Transplantation
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07371923
Application of Zanubrutinib-based Combination Regimens in the Treatment of Newly-diagnosed Diffuse Large B-cell Lymphoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06647940
Orelabrutinib in Combination with R-CHOP for CD5-positive DLBCL Patients（Rocket Trial）
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05487170
A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)
正在招募
阶段未标明
药物
clinicaltrials.gov
NCT06832228
Study of Pomalidomide Combination with Rituximab and Anti-PD-1 Antibody （PPR） in Third or Later Line Therapy of DLBCL
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06652165
Zanubrutinib Combined With BEAM for ASCT in Relapsed and Refractory DLBCL
正在招募
Phase 2
药物手术/操作
clinicaltrials.gov
NCT06682130
Glofitamab Bridging ASCT for Patients With Relapsed or Refractory DLBCL
即将招募
Phase 2
药物其他放疗
clinicaltrials.gov
NCT07634289
Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse Large B Cell Lymphoma
即将招募
Phase 1
药物
clinicaltrials.gov
NCT07424833
A Study of APG-3288 in Relapsed/Refractory Blood Cancers
即将招募
Phase 3
药物
clinicaltrials.gov
NCT06573645
A Phase III Clinical Trial of High-dose Rituximab (500mg/m²) Combined With CHOP Regimen in the Treatment of Male Patient With Newly Diagnosed Advanced DLBCL
正在招募
Phase 2
器械药物
clinicaltrials.gov
NCT06828991
A Study to Evaluate the Impact of Mosunetuzumab Consolidation for Older Patients With Diffuse Large B-cell Lymphoma (DLBCL) Who Have Detectable Amounts of ctDNA (Circulating Tumor DNA) at the End of Treatment With Pola-R-mini-CHP
即将招募
阶段未标明
生物制剂
clinicaltrials.gov
NCT07412405
This Clinical Trial is a Single-arm, Non-randomized Pilot Trial to Determine the Safety of Administering Autologous Anti-C19 Cells (ARI-0001) and the Feasibility of Local CAR-T Cell Production in Patients Over 18 Years of Age With Relapsed/Refractory (R/R) CD19+ Hematologic Malignancies, Including R
正在招募
Phase 2
药物
clinicaltrials.gov
NCT04889716
CAR-T Followed by Bispecific Antibodies
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06375733
A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06503263
Zanubrutinib and Lenalidomide as Maintenance Therapy in DLBCL
正在招募
Phase 3
药物
clinicaltrials.gov
NCT04332822
A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma
即将招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07269639
Golcadomide, Poseltinib, and Rituximab for Relapsed/Refractory Diffuse Large B-cell Lymphoma
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07197307
Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06530511
Polatuzumab, Rituximab and Orelabrutinib Combination Regimen (PRO) in the Treatment of Elderly Frail Patients with Treatment-naive Non-GCB DLBCL
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07451652
Low Dose Epcoritamab Plus GemOx in R/R DLBCL
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06414148
MRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma
正在招募
Phase 1, Phase 2
生物制剂
clinicaltrials.gov
NCT05326243
Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma
即将招募
Phase 2
药物
clinicaltrials.gov
NCT05280626
First-line Treatment of P53 Mutation With PD-L1 Expression in DLBCL With Anti-PD-1 Mab and R-CHOP
正在招募
Phase 3
药物
clinicaltrials.gov
NCT04442412
Prephase Treatment With Prednisone +/- Vitamin D Supplementation Followed by Immunochemotherapy
正在招募
Phase 2, Phase 3
生物制剂
clinicaltrials.gov
NCT07502118
NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19)
正在招募
Phase 2
生物制剂
clinicaltrials.gov
NCT07288879
DALY II Japan/MB-CART2019.1 for DLBCL
正在招募
Phase 1
基因治疗
clinicaltrials.gov
NCT05836896
A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies
正在招募
Phase 3
药物
clinicaltrials.gov
NCT07493109
Chidamide for Maintenance Treatment of HBV-infected Diffuse DLBCL in Patients Initially Treated With R-CHOP
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06664411
Pola-ZR2P in Previously Untreated DLBCL
正在招募
Phase 1
药物放疗
clinicaltrials.gov
NCT05950802
Optimizing lymphoDepletion to Improve Outcomes In Patients Receiving Cell Therapy With Yescarta
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06651853
Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06652139
Selinexor Combined With BEAM for ASCT in R/R DLBCL With MYC Positive
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06765317
A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma
正在招募
Phase 1
药物
clinicaltrials.gov
NCT05365659
IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas
即将招募
Phase 3
药物
clinicaltrials.gov
NCT07570823
A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07489989
Enhancing CAR-T Cell Therapy Efficacy in B-cell Lymphoma Via Chidamide and PD-1 Inhibitor Combination.
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07654426
The CARDIOPROTECT Trial
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07493148
Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL
正在招募
Phase 2
生物制剂药物
clinicaltrials.gov
NCT04792489
DALY II USA/ MB-CART2019.1 for DLBCL
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06516978
A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL
正在招募
Phase 3
生物制剂药物
clinicaltrials.gov
NCT06717347
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT06464861
Sequential Treatment of CD19 CARNK and 7x19 CAR-T in R/R B Cell Lymphoma
正在招募
EARLY / Phase 1
药物
clinicaltrials.gov
NCT06120166
Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07680933
Orelabrutinib Combined With Standard Immunochemotherapy With or Without Autologous Hematopoietic Stem Cell Transplantation (Auto-HSCT) for Newly Diagnosed Diffuse Large B-cell Lymphoma (DLBCL)
正在招募
Phase 3
药物
clinicaltrials.gov
NCT07011056
A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell Lymphoma
正在招募
阶段未标明
放疗
clinicaltrials.gov
NCT05514327
A Study of Ultra-fraction Radiotherapy Bridging CART in R/R DLBCL
正在招募
Phase 2
药物基因治疗
clinicaltrials.gov
NCT04844866
Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06701357
CR-CHOP+X in Previously Untreated DEL
正在招募
Phase 1
药物
clinicaltrials.gov
NCT04830137
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
正在招募
阶段未标明
放疗
clinicaltrials.gov
NCT02964858
Radiation Dose Optimization in Diffuse Large B- Cell Lymphoma.
正在招募
Phase 2
生物制剂药物
clinicaltrials.gov
NCT05952024
Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL
正在招募
Phase 1
药物
clinicaltrials.gov
NCT05107674
A Study of NX-1607 in Adults With Advanced Malignancies
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07126236
Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relapse/Refractory Large B Cell Lymphoma
即将招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07601607
Lisaftoclax Plus Chidamide and Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06748521
Dynamic CtDNA-guided Targeted Therapy in DLBCL
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05826535
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
正在招募
Phase 2
生物制剂药物
clinicaltrials.gov
NCT04002947
Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06760039
Safety and Efficacy of R-CMOP Versus R-CHOP in the Initial Treatment of DLBCL
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06594640
R-CMOP in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07387848
Glofitamab as a Bridge to and/or Consolidation Post Autologous Stem Cell Transplant in Patients With Relapsed B Cell Lymphomas
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07397832
CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL
正在招募
Phase 2
生物制剂药物
clinicaltrials.gov
NCT05757219
Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07326371
Glofitamab Combined With CAR-T Therapy in R/R DLBCL
正在招募
EARLY / Phase 1
生物制剂药物
clinicaltrials.gov
NCT04512716
Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma
正在招募
Phase 3
药物
clinicaltrials.gov
NCT07409428
A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06674096
RLC Followed by CR-CHOP in Elderly Patients with Newly-diagnosed DEL
即将招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07609862
A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies
正在招募
Phase 2
药物
clinicaltrials.gov
NCT03936153
Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
即将招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07415980
Phase Ib/II Study of Polatuzumab Vedotin in Combination With Rituximab and Chidamide in Newly Diagnosed Elderly Patients With Double-Expressor DLBCL
正在招募
Phase 1
药物
clinicaltrials.gov
NCT05131022
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06891157
Chidamide Plus R-CHOP in Newly Diagnosed Double-Expressor Diffuse Large B-Cell Lymphoma With Other Molecular Subtypes
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07078500
Orelabrutinib Combined With Pola-R-CHP Regimen for the Treatment of Untreated Non-GCB Diffuse Large B-Cell Lymphoma
正在招募
Phase 1
生物制剂药物放疗
clinicaltrials.gov
NCT07478848
Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07259070
Multicenter, Single-Arm Exploratory Phase I Clinical Study (Assessment of Safety and Efficacy) of Fully Human BAFF-R Chimeric Antigen Receptor T-Cell Injection in Relapsed/Refractory BAFF-R-Positive B-Cell Lymphoma
正在招募
Phase 2
基因治疗
clinicaltrials.gov
NCT07062627
Anbalcabtagene Autoleucel in Relapsed/Refractory CNS Lymphoma
正在招募
Phase 1
药物放疗
clinicaltrials.gov
NCT07528352
External Beam Radiotherapy Followed by Bispecific Antibody Therapy for Relapsed/Refractory DLBCL
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07255963
Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCL
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06220032
Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06669143
Zanubrutinib-based Maintenance Therapy of Newly Diagnosed DLBCL With Initial Remission
正在招募
Phase 1
药物
clinicaltrials.gov
NCT05544019
Study of SGR-1505 in Mature B-Cell Neoplasms
正在招募
阶段未标明
药物
clinicaltrials.gov
NCT06832267
Rituximab-Methotrexate-Temozolomide-Thiotepa (RMTT) Regimen As First-line Therapy for PCNS DLBCL
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07494565
Celecoxib Plus R-CHOP vs R-CHOP in Newly Diagnosed Advanced CD5+ DLBCL
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06758037
Clinical Study of HiR+X Therapy for Newly Diagnosed Elderly Patients With DLBCL Intolerant to Chemotherapy
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06811272
Outpatient Epcoritamab as 2L in NTE R/R DLBCL
正在招募
Phase 1
药物
clinicaltrials.gov
NCT05512390
A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06287398
Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCL
正在招募
Phase 2, Phase 3
药物
clinicaltrials.gov
NCT07084662
Xinlikang Capsule for Chemotherapy-induced Fatigue and Immune Disorders in Diffuse Large B Lymphoma
正在招募
Phase 1, Phase 2
联合产品药物
clinicaltrials.gov
NCT03356054
Phase I-II Study in CD30 Positive Diffuse Large B-cell Lymphoma Patients Refractory to First Line Chemotherapy or in First Relapse
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05552937
Evaluate the Safety and Efficacy of Tafasitamab Combined With Lenalidomide in Patients With Relapsed or Refractory DLBCL
即将招募
Phase 2, Phase 3
药物
clinicaltrials.gov
NCT06355401
Maintenance Hormonal Therapy and DLBCL
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07122609
Pirtobrutinib in Combination With Rituximab, Gemcitabine, Oxaliplatin With or Without Polatuzumab Vedotin in Covalent BTK Inhibitor-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT06544265
SynKIR-310 for Relapsed/Refractory B-NHL
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05294731
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
正在招募
Phase 2, Phase 3
生物制剂药物
clinicaltrials.gov
NCT05139017
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07677813
Orelabrutinib Combined With Induction Therapy Followed by Sequential Monotherapy Maintenance in MCD Subtype Diffuse Large B-cell Lymphoma
即将招募
阶段未标明
药物
clinicaltrials.gov
NCT07389356
Modified R-MINE Regimen vs. R-GemOx Regimens on the Treatment of Late Relapsed DLBCL
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06132503
Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07473167
Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06980116
Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06925555
Brentuximab Vedotin Combined With R-CHP in Newly Diagnosed EBV+ DLBCL-NOS
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06977711
Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL)
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06086197
A-RGEMOX in the Treatment of Early Relapsed/Refractory DLBCL
即将招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07643805
Single-Arm Clinical Study of EZH2i in Combination With Glofitamab + GemOx in Patients With Relapsed/ Refractory DLBCL
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06683885
A Prospective Clinical Study of the Combination Therapy of Obutinib or Decitabine with Rituximab, Cyclophosphamide, and Prednisone for the Primary Treatment of Elderly Patients with Newly Diagnosed Diffuse Large B-cell Lymphoma
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06594432
Molecular Subtype-Guided R-CHOP-MTX±Zanubrutinib Treatment in Newly Diagnosed DLBCL Patients with Central Nervous System Involvement
正在招募
Phase 1
联合产品
clinicaltrials.gov
NCT05659628
CD19 CAR-T Expressing IL-7 and CCL19 Combined With Anti-PD1 in RR-DLBCL
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06176729
Pola-R2 in Newly Diagnosed Non-fit Elderly DLBCL Patients
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06151080
Lenalidomide Combined With G-CHOP in the Treatment of Newly Diagnosed DLBCL With FL
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07254754
Study to Evaluate the Efficacy of Axicabtagene Ciloleucel in Patients With Late Relapse of Diffuse Large B-Cell Lymphoma
正在招募
Phase 1
生物制剂药物手术/操作
clinicaltrials.gov
NCT05272384
Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06570447
Glofitamab Combination With Chidamide in Patients With Recurrent/Refractory DLBCL
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06022029
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06005870
Zanubrutinib Combined With R-CHOP in the Treatment of Newly Diagnosed DLBCL With p53 Protein Expression
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06764017
CHiR Therapy for Elderly DLBCL Intolerant to Chemo
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07608978
Efficacy and Safety of Polatuzumab Vedotin in Combination With Zanubrutinib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma of the MCD/BN2/N1 Subtypes
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07124936
A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07260812
KSV01 Injection for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07249905
Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma
正在招募
Phase 2
生物制剂
clinicaltrials.gov
NCT06854159
Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07523737
Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma
正在招募
阶段未标明
药物
clinicaltrials.gov
NCT07006012
RGL-305+ Lymphoma + Exploratory Clinical Study
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06867536
Hypofractionation Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse B-cell Lymphoma With Baseline High Tumor Burden
即将招募
Phase 3
药物
clinicaltrials.gov
NCT07511114
A Study Comparing C Pola R-CHP+X With CR-CHOP in the Treatment of Previously Untreated DEL Under the Guidance of Genotyping
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07542678
Double-T - Improving Outcomes in High-risk 2nd Line Relapsed/Refractory Large B-Cell Lymphoma Patients Eligible for CAR-T-cell Therapy With a Glofitamab-based Induction and Consolidation Concept
正在招募
Phase 2
生物制剂药物
clinicaltrials.gov
NCT06890884
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06441097
Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07552324
Study on the Treatment of Double/Triple-hit DLBCL With Chidamide and Lisaftoclax in Combination With Pola-R-CHP
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07499271
Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 Mutation
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT06830031
Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma
正在招募
Phase 2
生物制剂
clinicaltrials.gov
NCT06534762
Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT07121946
This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06789159
A Phase Ib Study of VK-2019 in Patients With Relapsed or Refractory EBV+ Diffuse Large B-cell Lymphomas (DLBCL)
即将招募
Phase 2
药物其他
clinicaltrials.gov
NCT06594939
Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT06047197
Phase I Clinical Trial of RC19D2 Cell Injection in the Treatment of Diffuse Large B-cell Lymphoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05641428
Comparison of Point-of-care Produced CAR T-cell with Commercial CAR T-cells in Patients with R/R LBCL
正在招募
Phase 2
生物制剂药物手术/操作
clinicaltrials.gov
NCT07365306
Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07691606
A Study of ARC-02 in B-cell NHL
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06521255
Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT04920617
DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
即将招募
Phase 1
药物
clinicaltrials.gov
NCT07570017
A Study of Rocbrutinib Combined With R-GemOx in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06757894
Efficacy and Safety of Zuberitamab Combined with Bendamustine, Followed by Monotherapy Maintenance, in Treatment-naïve Follicular Lymphoma
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06284122
Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05950165
A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06961500
Obinutuzumab With CHOP Versus Obinutuzumab With Bendamustine in the Treatment of Newly Diagnosed Follicular Lymphoma Grade 3A
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06091254
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06510361
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05958719
Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07031700
A Multicenter, Single-Arm, Open-Label, Phase II Trial of Mosunetuzumab in Combination With Tislelizumab for r/r FL
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT04390737
Evaluate the Safety and Clinical Activity of HH2853
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06026319
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
正在招募
Phase 1
生物制剂药物
clinicaltrials.gov
NCT04545762
Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
正在招募
Phase 3
药物
clinicaltrials.gov
NCT04834024
MIL62 Combined With Lenalidomide Versus Lenalidomide for Patients With Rituximab Refractory Follicular Lymphoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06792825
HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05389293
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT02393157
Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL
正在招募
Phase 1, Phase 2
生物制剂
clinicaltrials.gov
NCT07519772
A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
正在招募
Phase 2
药物
clinicaltrials.gov
NCT04587687
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT04792502
Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06826118
Axicabtagene Ciloleucel Injection in Patients With Relapsed/Refractory Follicular Lymphoma
正在招募
Phase 1
生物制剂药物
clinicaltrials.gov
NCT05077527
Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06911502
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
即将招募
Phase 1
药物
clinicaltrials.gov
NCT07101328
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
正在招募
Phase 1
药物
clinicaltrials.gov
NCT05602363
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06959732
Zanubrutinib Combined With G-CVP in Previously Untreated FL
正在招募
Phase 3
生物制剂手术/操作
clinicaltrials.gov
NCT06337318
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06563596
Epco, Zanu, Ritux for R/R FL or MZL
正在招募
Phase 2
生物制剂药物手术/操作
clinicaltrials.gov
NCT04195633
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06340737
AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
正在招募
Phase 3
药物放疗
clinicaltrials.gov
NCT05045664
Early Stage Follicular LymphOma and RadioTherapy PLUS Anti-CD20 Antibody
正在招募
Phase 2
药物
clinicaltrials.gov
NCT04998669
Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma
正在招募
Phase 1, Phase 2
生物制剂手术/操作
clinicaltrials.gov
NCT07098364
ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma
正在招募
Phase 1, Phase 2
基因治疗
clinicaltrials.gov
NCT06533579
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT06703892
A Study to Evaluate the Safety and Clinical Activity of GF- CART01 (CD20/19 CAR T Cell) in Subjects With Relapsed or Refractory B-Cell Hematological Malignancies
正在招募
Phase 2
生物制剂
clinicaltrials.gov
NCT07128641
Odronextamab in Low Tumor Volume Advanced FL
正在招募
阶段未标明
联合产品
clinicaltrials.gov
NCT05040555
R-CDOP Regimen in the Treatment of Newly Diagnosed Non-Hodgkin's Lymphoma With High Tumor Burden
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07585747
A Exploratory Study on Untreated Follicular Lymphoma With Orelabrutinib, Tafasitamab, and Lenalidomide
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07226843
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
正在招募
Phase 1
药物
clinicaltrials.gov
NCT04234048
Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
正在招募
Phase 1, Phase 2
生物制剂
clinicaltrials.gov
NCT06213636
Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL).
正在招募
Phase 1
药物
clinicaltrials.gov
NCT04775745
Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT04110301
MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL)
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06947967
Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06492837
Study With Mosunetuzumab and Zanubrutinib in R/R Follicular Lymphoma Patients
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07191249
A Phase 2, Multicenter, Open-Label Trial to Evaluate Efficacy and Safety of Subcutaneous (SC) Mosunetuzumab in Previously Untreated Low Tumor Burden Follicular Lymphoma (LTB-FL).
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06918015
Zanubrutinib Plus GCVP (Obinutuzumab, Cyclophosphamide, Vindesine, Prednisolone) in Previously Untreated Follicular Lymphoma
正在招募
Phase 1, Phase 2
生物制剂
clinicaltrials.gov
NCT04186520
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
正在招募
Phase 3
药物
clinicaltrials.gov
NCT01804686
A Long-term Extension Study of PCI-32765 (Ibrutinib)
正在招募
Phase 1, Phase 2
生物制剂
clinicaltrials.gov
NCT05643742
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
正在招募
Phase 1
生物制剂药物手术/操作
clinicaltrials.gov
NCT06191887
B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies
即将招募
Phase 1
药物
clinicaltrials.gov
NCT07225439
Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
正在招募
Phase 1
生物制剂药物手术/操作
clinicaltrials.gov
NCT06209619
CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06045910
A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies
正在招募
阶段未标明
药物
clinicaltrials.gov
NCT07126678
Fixed-Duration Zanubrutinib, Bendamustine, and Obinutuzumab (ZBG) in Treatment-Naïve Advanced Stage Follicular Lymphoma
正在招募
Phase 1
药物
clinicaltrials.gov
NCT04223765
Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07545603
Clinical Study of XNW5004 Tablets in the Treatment of Relapsed and Refractory Follicular Lymphoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06347653
Linperlisib-based Treatment Regimen in Newly Diagnosed Nodal T-follicular Helper Cell Lymphoma (nTFHL)
即将招募
Phase 3
药物
clinicaltrials.gov
NCT07355283
IMM0306 in Combination With Lenalidomide vs Placebo in Combination With Lenalidomide in Patients With Relapsed/Refractory Follicular Lymphoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07555470
Mosunetuzumab and Zeprumetostat in Treating Patients With Follicular Lymphoma
正在招募
Phase 1
药物
clinicaltrials.gov
NCT05990465
LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
即将招募
Phase 2
生物制剂
clinicaltrials.gov
NCT07360288
Efficacy and Safety of TC011 in Relapsed or Refractory Follicular Lymphoma
正在招募
Phase 3
放疗
clinicaltrials.gov
NCT07029217
A Study of Reduced Dose Radiation Therapy for People With B-Cell Lymphomas
正在招募
Phase 1
生物制剂药物
clinicaltrials.gov
NCT07343934
huCART19-IL18-eDHFR Cells in Relapsed/Refractory Follicular Lymphoma
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05230680
Azacitidine-CHOP for Patients With Nodal T-cell Lymphoma With T-follicular Helper Phenotype (ACANTUS)
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06158386
Chidamide Combined With Linperlisibon for the Treatment of Refractory/Relapsed Follicular Lymphoma
正在招募
Phase 1, Phase 2
生物制剂药物
clinicaltrials.gov
NCT04669171
A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma
正在招募
Phase 1
药物
clinicaltrials.gov
NCT03460977
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05849857
Mosunetuzumab for Early Relapse of Follicular Lymphoma in the Nordic Countries
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05006716
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05783609
Epcoritamab and Rituximab for First-line Follicular Lymphoma
正在招募
Phase 3
药物
clinicaltrials.gov
NCT05100862
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06043323
A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06522737
A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype
正在招募
Phase 2
生物制剂药物放疗
clinicaltrials.gov
NCT05805605
Allo HSCT Using RIC and PTCy for Hematological Diseases
正在招募
Phase 2
生物制剂药物手术/操作
clinicaltrials.gov
NCT06834373
Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy
正在招募
Phase 2
生物制剂药物手术/操作
clinicaltrials.gov
NCT06905509
Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06368167
A Phase II Study of SHR2554 in Patients With Relapsed or Refractory Follicular Lymphoma
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06549595
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06474481
Zanubrutinib and G-CHOP in Untreated Intermediate-high Risk Follicular Lymphoma
正在招募
Phase 1
药物
clinicaltrials.gov
NCT05984147
A Study Evaluating the Safety and Efficacy of AUR108 in Patients With Relapsed Advanced Lymphomas (ASHA-1)
正在招募
Phase 2
生物制剂药物
clinicaltrials.gov
NCT06471738
Combination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular Lymphoma
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06549335
Zanubrutinib, Obinutuzumab and Lenalidomide (ZGR) in High-risk Treatment-naive Patients with Follicular Lymphoma (FL)
正在招募
Phase 3
药物其他手术/操作
clinicaltrials.gov
NCT06724237
Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy
正在招募
阶段未标明
放疗
clinicaltrials.gov
NCT04097067
ISRT 20 Gy for Indolent Localized Gastrointestinal (GI)-Lymphoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05281809
Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia
即将招募
Phase 1
生物制剂药物
clinicaltrials.gov
NCT07024147
JWCAR239 in Patients With B Cell Non-Hodgkin Lymphoma
正在招募
Phase 2, Phase 3
生物制剂药物
clinicaltrials.gov
NCT07634471
A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06350318
Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas
正在招募
Phase 1, Phase 2
生物制剂药物手术/操作
clinicaltrials.gov
NCT06536049
Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06561048
Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
正在招募
Phase 2
生物制剂
clinicaltrials.gov
NCT07587840
CD19/CD22 CAR-T as First-line Consolidation in Follicular Lymphoma
正在招募
Phase 2
生物制剂药物手术/操作
clinicaltrials.gov
NCT07042438
Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T Cells
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07505849
ZR2 Versus R2 Regimen in the Treatment of Newly Diagnosed Follicular Lymphoma
正在招募
Phase 2
生物制剂药物手术/操作
clinicaltrials.gov
NCT03125642
Auto Stem Cell Transplant for Lymphoma Patients
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07077512
Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma
即将招募
Phase 3
药物
clinicaltrials.gov
NCT07187960
Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular Lymphoma
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07535762
Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Untreated Peripheral T-Cell Lymphoma
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT04491370
Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05572983
Phase Ⅱ Study of Chidamide in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06550141
Emapalumab Prevention of CAR-T Cell Associated Toxicities
即将招募
Phase 3
药物
clinicaltrials.gov
NCT07562022
A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05848765
Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06553352
Zanubrutinib in Combination With Obinutuzumab (ZO) for Newly Diagnosed Follicular Lymphoma
正在招募
Phase 1, Phase 2
生物制剂药物
clinicaltrials.gov
NCT03676504
Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06149286
A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07299149
Zanubrutinib, Obinutuzumab Combined With Lenalidomide (ZGR) for the Treatment of Untreated Follicular Lymphoma
正在招募
Phase 3
其他放疗
clinicaltrials.gov
NCT05929222
Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana Linfomi
正在招募
Phase 2
生物制剂药物其他
clinicaltrials.gov
NCT05633615
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07550855
Sonrotoclax, Zanubrutinib and Rituximab in Previously Untreated Patients With Follicular Lymphoma
正在招募
Phase 2
药物放疗
clinicaltrials.gov
NCT06704555
Radiotherapy Followed by Tiselizumab Combined With RCHOP in Previously Untreated Bulky Follicular Lymphoma
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06191744
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
正在招募
Phase 2
生物制剂
clinicaltrials.gov
NCT03314974
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07418190
Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Relapsed/Refractory Follicular Lymphoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT04989621
Orelabrutinib Plus Rituximab Followed by Maintenance With Orelabrutinib for Relapsed and Refractory Follicular Lymphoma(RR FL)
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06526793
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06324994
Linperlisib Plus Obinutuzumab and Venetoclax for Relapsed and Refractory Blastoid Variant of Mantle Cell Lymphoma.
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07593482
Bendamustine Versus Fludarabine/Cyclophosphamide for Lymphodepletion in Chimeric Antigen Receptor T-cell Immunotherapy (CAR-T): a Randomized Trial.
正在招募
Phase 4
生物制剂
clinicaltrials.gov
NCT04460235
Clinical Trial Assessing the Immunogenicity of an Anti-pneumococcal Vaccination Strategy (PCV13+PPV23 Versus PREVENAR20) in Adult Patients Treated for a Lymphoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05635162
Zanubrutinib Plus Rituximab for Patients With Indolent Mantle Cell Lymphoma
正在招募
Phase 3
器械药物
clinicaltrials.gov
NCT07300514
Golidocitinib Versus Placebo as Maintenance Therapy for Peripheral T-Cell Lymphoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06341556
A Multicenter, Prospective, Phase II Study of Zanubrutinib for Maintenance in Patients With Mantle Cell Lymphoma
正在招募
Phase 2, Phase 3
生物制剂药物
clinicaltrials.gov
NCT05991388
A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06263491
Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07448324
Orelabrutinib Combined With Rituximab ± Lenalidomide in Response-Adapted Stratified Therapy for Untreated MZL
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06929624
A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma
正在招募
Phase 1, Phase 2
生物制剂
clinicaltrials.gov
NCT06420076
Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T Cells
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05934513
A Study of GFH009 Monotherapy in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
正在招募
EARLY / Phase 1
生物制剂手术/操作放疗
clinicaltrials.gov
NCT05800405
Evaluation of Bridging Radiation Therapy Before CAR T-Cell Infusion for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma
正在招募
Phase 1
药物
clinicaltrials.gov
NCT04807881
Phase Ib Clinical Study of Keynatinib
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06792734
Phase 1 Trial of BTM-3566 in Relapsed/Refractory Mature B Cell Lymphomas
即将招募
Phase 1
生物制剂药物
clinicaltrials.gov
NCT07575893
CD30 CAR-T Cells for Low Risk Relapsed Classical Hodgkin Lymphoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06846489
Acalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantle Cell Lymphoma
正在招募
阶段未标明
药物
clinicaltrials.gov
NCT06940960
JY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ Leukemia
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05475925
A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
正在招募
Phase 2
生物制剂
clinicaltrials.gov
NCT06479356
CD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell Lymphoma
正在招募
Phase 2
药物放疗
clinicaltrials.gov
NCT07554898
Ultra-low-dose Radiation Therapy Followed by Orelabrutinib as First-line Treatment for Stage Ⅰ-Ⅱ MALT Lymphoma
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07032532
Assessing An Oral JAK1 Inhibitor, Golidocitinib, in Patients Who Have Newly Diagnosed Peripheral T-Cell Lymphoma (JACKPOT23)
正在招募
Phase 1
药物手术/操作
clinicaltrials.gov
NCT07532525
Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma
即将招募
Phase 2
药物
clinicaltrials.gov
NCT05627115
Response Adapted Incorporation of Tislelizumab Into the Front-line Treatment of Older Patients With Hodgkin lYmphoma
正在招募
Phase 2
生物制剂药物手术/操作
clinicaltrials.gov
NCT06054776
Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06445517
Study Evaluating ISM8207 in Participants With Advanced Solid Tumors and Relapsed/Refractory B-Cell Lymphoma
正在招募
Phase 1, Phase 2
药物手术/操作
clinicaltrials.gov
NCT07069699
Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06698484
To Evaluate Safety and Efficacy of Autologous CD19 Chimeric Antigen Receptor (CAR)-T Cells in Relapsed/Refractory B- Non-Hodgkin Lymphoma (B-NHL)
正在招募
Phase 3
药物
clinicaltrials.gov
NCT04638790
First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia (HL-Russia-1)
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06755450
Study Evaluating Safety Pharmacokinetics and Pharmacodynamics of AUR112 in Patients With Relapsed Advanced Lymphoma
正在招募
Phase 3
药物
clinicaltrials.gov
NCT07234162
A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)
正在招募
阶段未标明
药物
clinicaltrials.gov
NCT07257510
Pomalidomide Plus Orelabrutinib and Zuberitamab in Untreated Mantle Cell Lymphoma
即将招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07535710
Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Treated Cutaneous T-cell Lymphoma
正在招募
Phase 3
药物
clinicaltrials.gov
NCT05254743
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
正在招募
Phase 1, Phase 2
联合产品药物
clinicaltrials.gov
NCT05300282
Study of Atezolizumab Plus BEGEV Regimen in Relapsed or Refractory Hodgkin's Lymphoma Patients
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07387471
Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05977673
Efficacy and Safety of Frontline Tislelizumab in Patients With de Novo Hodgkin Lymphoma Unsuitable for Standard Frontline Chemotherapy
即将招募
Phase 2
药物其他
clinicaltrials.gov
NCT07654465
Rituximab Maintenance Versus Observation After R2 Induction in Previously Untreated Marginal Zone Lymphoma
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06902012
Safety and Efficacy of Early Second Infusion of Axi-cel Based on ctDNA for R/R Large B - Cell Lymphoma
正在招募
Phase 1
生物制剂药物手术/操作
clinicaltrials.gov
NCT05418088
Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05249959
Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients.
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05955105
A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06176027
Azacytidine Plus CAOLD Regimen in Relapsed/Refractory Peripheral T-Cell Lymphomas
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06919679
Phase II Trial of BrECADD in HIV-Positive Patients With Advanced-Stage Classical Hodgkin Lymphoma
即将招募
Phase 3
药物
clinicaltrials.gov
NCT07516093
Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05949944
Linperlisib in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma
正在招募
Phase 2
药物其他
clinicaltrials.gov
NCT06365671
CAR-T Following ASCT for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (R/R B-NHL) With High-Risk Prognostic Factors
正在招募
Phase 1
药物
clinicaltrials.gov
NCT05528055
A Study to Investigate the Safety and Tolerability of SCR-6920 Capsule in Patients With Advanced Malignant Tumors
正在招募
Phase 2
生物制剂药物
clinicaltrials.gov
NCT05884333
Cord Blood Transplant in Adults With Blood Cancers
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07441993
Exploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZL
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07658924
Efficacy and Safety of Benvitimod Cream in Cutaneous T-Cell Lymphoma
正在招募
Phase 2
生物制剂药物
clinicaltrials.gov
NCT05735717
MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
即将招募
阶段未标明
药物
clinicaltrials.gov
NCT05990985
The Efficacy and Safety of the RCMOP Sequential Therapy as a First-line Treatment for Patients With Intermediate-to-high Risk Diffuse Large B-cell Lymphoma Who Had Incomplete Remission.
正在招募
Phase 3
药物
clinicaltrials.gov
NCT07377578
A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma
正在招募
Phase 4
药物
clinicaltrials.gov
NCT06876649
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06206174
TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies
正在招募
阶段未标明
放疗
clinicaltrials.gov
NCT06883604
Clinical Investigation of Proton Treatment in Hodgkin Lymphoma Patients - PRO-Hodgkin
即将招募
Phase 1, Phase 2
生物制剂
clinicaltrials.gov
NCT07506668
RN1701 Injection in the Treatment of Relapsed/Refractory B-Cell Lymphomas
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05907759
Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease
即将招募
Phase 2
生物制剂手术/操作
clinicaltrials.gov
NCT07576725
Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial
正在招募
Phase 3
生物制剂
clinicaltrials.gov
NCT04094311
Study of Out of Specification for Tisagenlecleucel
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06447376
Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab
即将招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07209163
Combination Therapy With Tazemetostat in Relapsed and Refractory Peripheral T-cell Lymphoma
正在招募
Phase 2, Phase 3
药物
clinicaltrials.gov
NCT05595447
Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT04925609
Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT04094610
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
正在招募
Phase 1, Phase 2
生物制剂
clinicaltrials.gov
NCT05480449
Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06006117
Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma
正在招募
Phase 1
药物
clinicaltrials.gov
NCT05685173
A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas
即将招募
EARLY / Phase 1
药物
clinicaltrials.gov
NCT04609241
CD79b CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia and B-cell Non-Hodgkin's Lymphoma
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT06593145
CAR T Cells in the Treatment of Refractory and Relapsed CD19+ B Cell Neoplasms
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT04440436
Assessment of Safety and Efficacy of IM19 for Recurrent or Refractory (R/R) Non-Hodgkin's Lymphoma(NHL) Patients
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05529069
Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients
正在招募
Phase 1, Phase 2
生物制剂药物
clinicaltrials.gov
NCT06002659
CAR20(NAP)-T Therapy for B Cell Lymphoma (CARMA-01 Study)
正在招募
Phase 2
生物制剂药物手术/操作
clinicaltrials.gov
NCT06918431
Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
正在招募
阶段未标明
放疗
clinicaltrials.gov
NCT04368702
CONFIRM: Magnetic Resonance Guided Radiation Therapy
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06458439
Epcoritamab-CAR T Cells for Large B-cell Lymphomas
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06732492
RD13-02 Cell Injection in Patients with Relapsed or Refractory CD7-Positive Natural Killer/T Cell Malignancies
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06566807
Oxygen Study-Orelabrutinib Combined With Obinutuzumab(O2) for First-Line Treatment of Marginal Zone Lymphoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05245656
A Study Comparing Rituximab/Bendamustin(RB) Alternating With Rituximab/Bendamustin/Cytarabin(RBAC) With RB Therapy in Elderly Patients With Mentle Cell Lymphoma
正在招募
Phase 1
药物
clinicaltrials.gov
NCT04970901
A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
正在招募
Phase 2
药物
clinicaltrials.gov
NCT02859402
Allogeneic Stem Cell Transplantation in Relapsed/Refractory T-, NK/T-cell Lymphomas
即将招募
Phase 1
药物
clinicaltrials.gov
NCT07234045
A Clinical Study to Explore CT1195E in Patients With Relapsed/Refractory B-Cell Neoplasms
正在招募
Phase 1, Phase 2
基因治疗
clinicaltrials.gov
NCT06834529
CAR2219 CAR-T Cells for the Treatment of R/R B Cell Leukemia and Lymphoma
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT06696846
CD70-CAR-NK Cell Therapy for T Cell Lymphoma and Acute Myeloid Leukemia
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07283796
A Study to Assess PK, Safety and Efficacy of HSK47977 Tablets in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma
即将招募
Phase 2, Phase 3
生物制剂药物手术/操作
clinicaltrials.gov
NCT07572123
Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem Cell Transplant Alone for High-risk Patients With Relapsed or Refractory Hodgkin Lymphoma
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06470451
Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL
即将招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07432022
A Phase I/II Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of the EMB-07 Combination Therapy in Patients With Aggressive B-Cell Non-Hodgkin Lymphoma
正在招募
阶段未标明
药物
clinicaltrials.gov
NCT06961669
Intravenous Autologous CD19 CAR-T Cells for R/ R MM, B-ALL, and B-Cell Lymphoma
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT06313957
A Study of LUCAR-20SP in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05338931
Safety, Tolerability, and Efficacy of AT101 in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07072169
A Study of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL)
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05348213
Novel Targeted Drugs Combined With R-ICE Regimen in Relapsed and Refractory Diffuse Large B-cell Lymphoma
即将招募
Phase 1
生物制剂
clinicaltrials.gov
NCT07539610
Evaluation of the Safety and Efficacy of Sup19 CAR-T Cells in Patients With Previously Failed CD19-Targeted Therapy or CD19-Weakly Expressed Hematologic Tumors
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07460362
Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06066203
A Study of GNC-035 in Relapsed or Refractory Non-Hodgkin 's Lymphoma and Other Hematological Malignancies
即将招募
EARLY / Phase 1
药物
clinicaltrials.gov
NCT07213882
A Phase 1, Multicenter, Open-label, Prospective, First-in-human Dose-escalation Clinical Trial of Domain Therapeutics' Anti-CCR8 Monoclonal Antibody (DT-7012) in Patients With Relapsed or Refractory Cutaneous T-cell Lymphomas (CTCL)
正在招募
EARLY / Phase 1
生物制剂
clinicaltrials.gov
NCT06346912
CD19-BAFF CAR-T Cells Therapy for Patients With Relapsed / Refractory B-cell ALL and B-cell NHL
正在招募
EARLY / Phase 1
药物
clinicaltrials.gov
NCT04603872
CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05092451
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07439653
A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05533775
A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06045195
Pembrolizumab in First-Line Treatment of Advanced-Stage Classical Hodgkin Lymphoma
正在招募
Phase 1
生物制剂药物
clinicaltrials.gov
NCT03666000
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
正在招募
Phase 1
生物制剂药物
clinicaltrials.gov
NCT05333302
Pilot CAR-T Cells Therapy for Children/Young Adults With CD19+ R/R Leukemia/Lymphoma
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT04855695
Avo In R/R And Previously Untreated MCL
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06136351
A Study of the Zanubrutinib Given in Combination With Bendamustine and Rituximab in (Elderly or TP53 Alterations or Chemotherapy Intolerance) Patients With Newly Diagnosed Mantle Cell Lymphoma
正在招募
EARLY / Phase 1
药物手术/操作
clinicaltrials.gov
NCT04532203
A Study of CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Central Nervous System Hematological Malignancies
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT06707259
Clinical Study of Cord Blood-derived IL-10/IL-15 CD19-CAR NK in the Treatment of Refractory/Relapsed B-cell NHL
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06822868
A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT06334991
Study for Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07114367
NB02(POSELTINIB) Monotherapy in R/R Non-Hodgkin's Lymphoma
即将招募
Phase 1
药物
clinicaltrials.gov
NCT07068906
A Clinical Study Exploring CT1194C in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
正在招募
Phase 3
药物
clinicaltrials.gov
NCT05645107
A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06390956
Pirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma (PIONEER-MZL)
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT07368270
Safety and Efficacy Study of Anti-PD1 Armored CD19 CAR-T Cells in Adult Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07073833
The Safety, Tolerability, and Efficacy of IBR900 Cell Injection in Relapsed/Refractory B-cell Non Hodgkin Lymphoma
正在招募
Phase 1, Phase 2
生物制剂
clinicaltrials.gov
NCT04429438
Multi-CAR-T Cells Targeting B Cell Lymphomas
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06522555
The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell Lymphoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05833724
Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT06180174
Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/Refractory B Cell Lymphoma
即将招募
EARLY / Phase 1
生物制剂
clinicaltrials.gov
NCT07563543
RN1701 Injection in the Treatment of Relapsed/Refractory B-Cell Lymphomas
即将招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07607925
A Study to Evaluate Safety and Clinical Activity of GSK5926371 in Adult Participants With Relapsed or Refractory B-NHL
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07081607
Golidocitinib With Azacitidine and Chidamide in Patients With Peripheral T-cell Lymphoma.
正在招募
Phase 1
生物制剂药物手术/操作
clinicaltrials.gov
NCT04231877
Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT04512534
Sintilimab Combined With Chidamide in Treating Peripheral T Cell Lymphoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07231952
A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)
正在招募
Phase 1, Phase 2
生物制剂药物手术/操作
clinicaltrials.gov
NCT06357676
Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial
正在招募
Phase 1, Phase 2
生物制剂药物
clinicaltrials.gov
NCT06090864
ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07022964
CD5 CAR T-Cell Therapy for r/r T-cell Lymphomas
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06081478
CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06835530
A Combination of Rituximab and CC-99282 as Front-line Therapy for Older Frail Patients With Diffuse Large B-cells Non-Hodgkin Lymphoma Evaluated With a Simplified Geriatric Assessment (sGA): a Phase II Study of the Fondazione Italiana Linfomi (FIL)
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07000617
A Phase II Study of Dexamethasone, Azacitidine, Pegaspargase and Tislelizumab Plus Radiotherapy for Patients With Stage I/II Extranodal NK/T-cell Lymphoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06812858
PD-1 Inhibitors Maintenance for cHL Post-autoHCT
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT03328078
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT03829540
CD4CAR for CD4+ Leukemia and Lymphoma
正在招募
Phase 1, Phase 2
生物制剂药物
clinicaltrials.gov
NCT06321289
Allogeneic TRAC Locus-inserted CD19-targeting STAR T Cell Therapy in r/r B-NHL
正在招募
Phase 3
生物制剂药物
clinicaltrials.gov
NCT06170489
A Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-(L)1monoclonal Antibody Refractory Classic Hodgkin Lymphoma (cHL)
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07502768
Tislelizumab Plus Zeprumetostat for Relapsed or Refractory NK/T-Cell Lymphoma
正在招募
Phase 1, Phase 2
生物制剂药物
clinicaltrials.gov
NCT03223610
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06496308
Bendamustine and Rituximab With or Without Orelabrutinib in MCL Treatment
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06564038
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
即将招募
Phase 3
药物
clinicaltrials.gov
NCT07178457
Brentuximab Vedotin in CutAneous T-cell Lymphomas (CTCL): Post-allogeneic Hematopoietic Stem Cell Transplant Maintenance
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07272499
Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06916416
Phase II Trial of Anti-PD-1 Antibody Treatment and Radiotherapy in Early-stage Favorable Classic Hodgkin Lymphoma
正在招募
EARLY / Phase 1
药物
clinicaltrials.gov
NCT06716164
Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r B-NHL Clinical Research
正在招募
Phase 2, Phase 3
生物制剂药物
clinicaltrials.gov
NCT07202091
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Immunoglobulin Stopping or Extension (Stop Ig)
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT03681561
Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06915246
A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma
正在招募
Phase 2
器械药物
clinicaltrials.gov
NCT06954805
Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)
正在招募
Phase 2, Phase 3
药物放疗
clinicaltrials.gov
NCT06563245
Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment
正在招募
Phase 2
生物制剂药物手术/操作
clinicaltrials.gov
NCT04840602
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
即将招募
Phase 1
生物制剂
clinicaltrials.gov
NCT06314828
A Tolerability, Safety and Efficacy Study of RJMty19 in Subjects With Relapsed or Refractory B-NHL
正在招募
Phase 2
生物制剂药物
clinicaltrials.gov
NCT04871607
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
正在招募
Phase 1, Phase 2
生物制剂
clinicaltrials.gov
NCT03938987
Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL)
正在招募
Phase 1
药物手术/操作
clinicaltrials.gov
NCT02508038
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT06445803
CD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06028373
A Study of ATG-031 in Advanced Solid Tumors or B-cell Non-Hodgkin Lymphomas
正在招募
Phase 1, Phase 2
生物制剂药物
clinicaltrials.gov
NCT07009002
BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06665217
G-Pola-ZLP in Diffuse Large B-Cell Lymphoma
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT06934382
Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma
正在招募
Phase 2
生物制剂药物其他
clinicaltrials.gov
NCT02727803
Personalized NK Cell Therapy in CBT
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06486337
CMOP±R in the Treatment of Untreated Non-Hodgkin's Lymphoma
正在招募
Phase 1, Phase 2
药物手术/操作
clinicaltrials.gov
NCT04851119
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06829771
Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma
正在招募
Phase 3
药物
clinicaltrials.gov
NCT03647072
PPI Versus Histamine Antagnists as Adjuvant to Chemotherapy
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05182957
Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05806099
A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy Study of MBS303 in B-Cell NHL
正在招募
Phase 2
生物制剂药物其他
clinicaltrials.gov
NCT07275216
Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Standard Treatment
正在招募
Phase 4
药物
clinicaltrials.gov
NCT06831370
A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in India
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06503094
CD19 & CD20 Bispecific CAR T Cells for Relapsed / Refractory B Cell Hematological Tumors
即将招募
Phase 1
药物
clinicaltrials.gov
NCT06970496
A Clinical Trial of B019 Injection in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma.
正在招募
Phase 1
药物放疗
clinicaltrials.gov
NCT05296304
A Study of Bexarotene Combined With Radiotherapy in People With Mycosis Fungoides
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT05472558
Clinical Study of Cord Blood-derived CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06160843
Pembrolizumab and Olaparib Treatment for Relapsed or Refractory Peripheral T-Cell Lymphoma
正在招募
Phase 1, Phase 2
生物制剂
clinicaltrials.gov
NCT05674175
Co-administration of CART22-65s and huCART19 for B-ALL
即将招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07615283
Adebrelimab Combined With SHR2554 in Relapsed/Refractory PTCL and NK/T-Cell Lymphoma
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06792253
Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06484920
A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL
正在招募
Phase 1, Phase 2
生物制剂
clinicaltrials.gov
NCT06378190
Treatment of Relapsed or Refractory B-cell Lymphoma With Chimeric Antigen Receptor (CAR) T-cell Therapy Produced by a New Technology
正在招募
Phase 2
药物手术/操作
clinicaltrials.gov
NCT06687772
CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell Transplant
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05998642
Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma
正在招募
Phase 3
药物
clinicaltrials.gov
NCT05820841
Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma
即将招募
阶段未标明
药物
clinicaltrials.gov
NCT06879470
JY231(JY231) Injection for the Treatment of Relapsed or Refractory B-Cell Lymphoma
即将招募
Phase 3
放疗
clinicaltrials.gov
NCT07256158
PET Guided Dose Reduction for InvOlved Site Radiotherapy In Early sTage Unfavourable Hodgkin Lymphoma
正在招募
Phase 1, Phase 2
生物制剂药物
clinicaltrials.gov
NCT05442515
CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
正在招募
Phase 1
基因治疗
clinicaltrials.gov
NCT07220993
Novel Unedited Allo Cell Therapy For High Risk T-Cell Malignancies Using CD7-Specific Car T Cells
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06393738
A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.
正在招募
EARLY / Phase 1
生物制剂
clinicaltrials.gov
NCT07093411
Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06390319
Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
正在招募
Phase 4
生物制剂
clinicaltrials.gov
NCT06609304
Axicabtagene Ciloleucel for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma
正在招募
Phase 1
药物
clinicaltrials.gov
NCT05794958
Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel
正在招募
Phase 1
药物
clinicaltrials.gov
NCT04771572
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06701344
Go-CHOP in de Novo Intestinal T-cell Lymphoma Patients
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06090539
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
正在招募
Phase 2
生物制剂药物其他
clinicaltrials.gov
NCT07097363
Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma
正在招募
Phase 1
生物制剂药物手术/操作
clinicaltrials.gov
NCT06508463
Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07525466
Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatment of NK/T-cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis (NKTCL-HLH)
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07082803
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT06395870
Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
即将招募
阶段未标明
药物
clinicaltrials.gov
NCT07299331
Zanubrutinib, Rituximab, and Lenalidomide in the First-Line Treatment of Marginal Zone Lymphoma
正在招募
Phase 4
药物
clinicaltrials.gov
NCT07270835
Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma
正在招募
Phase 4
药物
clinicaltrials.gov
NCT06134284
Clinical Study of OR for Second-line Treatment of Refractory MZL
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07164469
Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma
正在招募
EARLY / Phase 1
药物
clinicaltrials.gov
NCT06976437
A Clinical Study of Allogeneic CD19/BCMA CAR-T Cells for the Treatment of R/R B-cell Malignant Tumors
即将招募
Phase 1
药物
clinicaltrials.gov
NCT07603479
A Phase I Study of JL19001 Injection Alone or in Combination With Standard Therapy in Patients With Advanced Solid Tumors or Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT04510636
Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma
即将招募
Phase 1
生物制剂
clinicaltrials.gov
NCT06894693
A Phase I Clinical Trial of RS001 in Patients with Relapsed/Refractory B-Cell Malignancies
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06060782
Thiotepa, Cyclophosphamide, Clarithromycin and Cytarabine
即将招募
Phase 1, Phase 2
生物制剂
clinicaltrials.gov
NCT06617286
CD30 CAR T-cells Post AutoHSCT for Poor-risk Hodgkin Lymphoma
正在招募
Phase 1, Phase 2
生物制剂药物手术/操作
clinicaltrials.gov
NCT05861050
Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06189391
A Study to Evaluate MK-1045 (CN201) in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (MK-1045-001/CN201-101)
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06487624
An Engineered Sirpα Fused to Anti-Pd-L1 And Tgf-β Fusion Protein (HCB301) in Subjects With Selected Advanced Tumors
正在招募
Phase 2, Phase 3
药物
clinicaltrials.gov
NCT07389616
A Clinical Trial of Cidabenamine Plus Azacitidine to Prevent Post-Transplant Progression in High-Risk Peripheral T-Cell Lymphoma
即将招募
Phase 4
生物制剂
clinicaltrials.gov
NCT06956092
Glofitamab for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma
正在招募
Phase 3
药物
clinicaltrials.gov
NCT07582432
A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06642792
A Study of AK129 With or Without AK117 in PD(L)1-refractory Classic Hodgkin Lymphoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06647732
Zanubrutinib Plus Rituximab as Front-line Treatment for Mucosa-associated Lymphoid Tissue Lymphoma (MALT)
正在招募
Phase 2
生物制剂药物手术/操作
clinicaltrials.gov
NCT05910801
Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
正在招募
Phase 1, Phase 2
生物制剂
clinicaltrials.gov
NCT06343311
T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
即将招募
Phase 1
药物
clinicaltrials.gov
NCT07166549
Bispecific CAR T Cells for B-cell Malignancies (BaseCAR-01 Trial)
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06519526
Exploratory Clinical Study of SHR-0302 and SHR-2554 in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT06758713
Safety and Efficacy of Fourth-Generation CAR-T in the Treatment of Hematologic Malignancies
正在招募
Phase 1, Phase 2
生物制剂
clinicaltrials.gov
NCT06874946
Nanobody-Based Anti-CD5 CAR-T for Relapsed/Refractory T-ALL/NHL
即将招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07339527
EZH2 Inhibitor Zeprumetostat in Combination Therapy for Patients With Relapsed or Refractory Mature T-cell and NK-cell Lymphomas
即将招募
EARLY / Phase 1
生物制剂
clinicaltrials.gov
NCT05779930
Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL and NHL
正在招募
Phase 1
基因治疗
clinicaltrials.gov
NCT01853631
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
即将招募
Phase 2
生物制剂药物手术/操作
clinicaltrials.gov
NCT07583810
Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06552559
Selinexor With ICE Chemotherapy in Secondary Central Nervous System Involving B-cell Non-Hodgkin Lymphoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06508099
Vitamin A and D Supplementation in Allogeneic HCT
即将招募
Phase 4
药物
clinicaltrials.gov
NCT06761911
BV in the Treatment of Relapsed/refractory Hodgkin Lymphoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05583071
Methotrexate, Tafasitamab, Lenalidomide and Rituximab in Patients With PCNSL
正在招募
阶段未标明
药物
clinicaltrials.gov
NCT06478472
Prospective Clinical Study of Orelabrutinib in Combination With Rituximab (OR) for Primary Marginal Zone Lymphoma (MZL) That Failed or Not Suitable for Local Therapy
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07029737
A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT05989204
TmCD19-IL18 in CD19+ Cancers
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07385989
Golidocitinib Combined With P-GemOx Plus PD-1 Inhibitor Versus P-GemOx Plus PD-1 Inhibitor in First-Line Newly Diagnosed Advanced or Non-Nasal Extranodal NK/T-Cell Lymphoma
正在招募
Phase 1
药物
clinicaltrials.gov
NCT05079282
Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma
正在招募
Phase 1
药物
clinicaltrials.gov
NCT05798897
Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
即将招募
Phase 1
生物制剂
clinicaltrials.gov
NCT07113496
RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies
即将招募
EARLY / Phase 1
生物制剂
clinicaltrials.gov
NCT07584850
Evaluation of GI001 for Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT04664179
EBV Specific T-Lymphocytes for Treatment of EBV-Positive Lymphoma
正在招募
Phase 2
药物手术/操作放疗
clinicaltrials.gov
NCT03779854
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
即将招募
Phase 1
生物制剂
clinicaltrials.gov
NCT07316920
A Clinical Study of of RN1701 Injection in the Treatment of Relapsed/Refractory B-Cell Lymphomas
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT07623850
A Phase I Study of JLM019 Injection
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06530550
PI3K Inhibitors for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas
正在招募
Phase 2
药物
clinicaltrials.gov
NCT04935684
Faecal Microbiota Transplantation After Allogeneic Stem Cell Transplantation
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05313243
Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma
正在招募
Phase 1
药物
clinicaltrials.gov
NCT04884035
Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT06725524
A Study of JMT601 in Participants With Relapsed or Refractory CD20-positive B-cell Non-Hodgkin Lymphoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07022223
Orelabrutinib Combined With Rituximab as First-line Systemic Treatment for Marginal Zone Lymphoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT04099966
AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06824883
Sintilimab, Pegaspargase Plus GemOx for Untreated Extranodal NK/T-Cell Lymphoma
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07551583
Phase 2 Study Of Nivolumab Plus AVD In Pediatric, Adolescent, And Young Adult Patients With CHL
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07457177
Phaes Ⅱ Study of Golidocitinib-Pegaspargase-PD-1 Antibody First-Line for Advanced ENKTL
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05355051
A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients Relapsed/Refractory Hodgkin's Lymphoma
正在招募
Phase 1
药物
clinicaltrials.gov
NCT05389423
Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT07451054
CD45BE-HSPC + CART-45 Cells
正在招募
Phase 2, Phase 3
药物
clinicaltrials.gov
NCT07168980
Chemotherapy With Rituximab for Aggressive B-NHL in Children and Adolescents
正在招募
Phase 1
生物制剂药物手术/操作
clinicaltrials.gov
NCT03017820
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06563778
Chidamide+Decitabine Plus Anti-PD-1 Antibody for Patients With R/R cHL Who Are Transplant-ineligible or Refused Transplant.
即将招募
Phase 2
药物放疗
clinicaltrials.gov
NCT07554482
Selinexor Combined With Reduced-Dose Radiotherapy For Early-Stage Extranodal NK/T-Cell Lymphoma
正在招募
Phase 1
药物
clinicaltrials.gov
NCT05169515
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT04104776
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
正在招募
Phase 1, Phase 2
生物制剂
clinicaltrials.gov
NCT03571568
A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHL
正在招募
Phase 1
药物
clinicaltrials.gov
NCT05741359
The Safety and Efficacy of BRL-201 in the Treatment of r/r B Lymphocyte Non-Hodgkin Lymphoma
即将招募
Phase 1
药物
clinicaltrials.gov
NCT07539688
Phase I Clinical Study on the Safety and Efficacy of CY-219 CAR-T Cell Injection in the Treatment of Relapsed/Refractory B-Cell Lymphoma
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07180771
A Study of Bosmolisib (BR101801) in Participants With R/R PTCL.
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT07106749
CD180 CART for Relapsed or Refractory CD180 Positive Hematologic Malignancies
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06735495
CD19 & CD22 Bispecific CAR T Cells in the Treatment of Relapsed/Refractory B Cell Hematologic Tumors
正在招募
Phase 2
生物制剂
clinicaltrials.gov
NCT03258567
Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas
即将招募
Phase 1
药物
clinicaltrials.gov
NCT04419909
Retreatment With CTL019/CTL119
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT06517004
An Open-label, Single-arm Study of JWCAR201 in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
正在招募
Phase 2
生物制剂
clinicaltrials.gov
NCT06796998
Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL)
正在招募
Phase 2
药物
clinicaltrials.gov
NCT03297606
Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05963347
Go-CHOP as the Frontline Therapy for PTCL
正在招募
Phase 1
生物制剂药物手术/操作
clinicaltrials.gov
NCT07166419
Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia
正在招募
Phase 1
药物手术/操作
clinicaltrials.gov
NCT05755087
Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma
即将招募
Phase 1
药物
clinicaltrials.gov
NCT06318884
A First-in-human Study of SCTB35 in Patients With Relapse/Refractory B-cell Non-Hodgkin Lymphoma
正在招募
Phase 4
药物放疗
clinicaltrials.gov
NCT03500133
Pediatric Hodgkin Lymphoma Treatment Trial With Low Cumulative Doses of Chemotherapy Agents and Reduced Radiation.
正在招募
Phase 1
生物制剂手术/操作
clinicaltrials.gov
NCT05432635
Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06739265
Golidocitinib Plus CHOP in Newly Diagnosed PTCL
正在招募
Phase 4
药物
clinicaltrials.gov
NCT05518383
B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06925464
CD7 CAR T-Cell Therapy for r/r T-cell Lymphomas
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07279584
Golidocitinib Combined With GemOx in RR PTCL
正在招募
EARLY / Phase 1
生物制剂药物
clinicaltrials.gov
NCT04139304
A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma
正在招募
Phase 2, Phase 3
生物制剂
clinicaltrials.gov
NCT07202065
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Dosing Immunoglobulin (Dose Ig)
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07444632
Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed/Refractory Lymphoid Malignancies
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07001384
A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL)
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06255704
A Single-arm, Single-center, Open-label Phase II Study of Zanubrutinib Combined With R-CHOP/R-DHAP in Newly Diagnosed Mantle CellLymphoma Patients
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT06494371
A Study of LCAR-HL30 in Subjects With Relapsed/Refractory Hodgkin's Lymphoma and Anaplastic Large Cell Lymphoma
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06421948
Linperlisib Combined With Chidamide in Patients With PTCL
即将招募
Phase 1, Phase 2
生物制剂药物手术/操作
clinicaltrials.gov
NCT07578077
Golcadomide in Combination With Rituximab for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma
正在招募
Phase 2
生物制剂其他手术/操作
clinicaltrials.gov
NCT05886036
Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial
正在招募
EARLY / Phase 1
生物制剂
clinicaltrials.gov
NCT07312630
Clinical Study of LV009 Injection for the Treatment of Relapsed/Refractory CD19-Positive Hematologic and Lymphoid Malignancies
正在招募
Phase 2
药物手术/操作
clinicaltrials.gov
NCT07356245
Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
正在招募
Phase 2
药物放疗
clinicaltrials.gov
NCT05253495
Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07144657
Prospective Study of Frontline Antibiotics Therapy in the Treatment of Early-stage HP-negative Gastric MALT Lymphoma
即将招募
EARLY / Phase 1
药物
clinicaltrials.gov
NCT05979857
Study of SP-3164 in Relapsed or Refractory Non-Hodgkin's Lymphoma
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05256641
Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma
即将招募
Phase 4
药物
clinicaltrials.gov
NCT05814848
A Study of Secondary Infusion of Relmacabtagene Autoleucel Injection for Relapsed or Refractory B-cell Lymphoma
即将招募
Phase 1
生物制剂
clinicaltrials.gov
NCT06385522
A Clinical Trial in Adults With Non-Hodgkin Lymphoma (NHL), With a Particular Emphasis on Cutaneous T Cell Lymphoma (CTCL), Testing the Safety and Activity of a Novel Drug to Inhibit a Protein Called Tumor Necrosis Factor Receptor 2 That Drives Both Lymphoma Growth and Escape of the Immune System
即将招募
Phase 1
生物制剂药物
clinicaltrials.gov
NCT07367685
Clinical Study of Universal CD19 CAR-γδT Cell Injection in the Treatment of Adult Relapsed/Refractory B-cell Lymphoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT04838652
Pembrolizumab in Combination With Salvage Chemotherapy for First-relapsed or Refractory Classical Hodgkin Lymphoma
即将招募
EARLY / Phase 1
药物
clinicaltrials.gov
NCT07003178
A Study to Evaluate the Safety and Clinical Efficacy of STR-P004
正在招募
Phase 1
药物
clinicaltrials.gov
NCT05659732
A Study of PEP07 (Checkpoint Kinase 1 Inhibitor) in Patients With Advanced Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT04961515
Orelabrutinib, Sintilimab and Temozolomide in Relapsed or Refractory Central Nervous System Lymphoma
正在招募
Phase 1
基因治疗
clinicaltrials.gov
NCT03081910
Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen
正在招募
Phase 1
生物制剂药物
clinicaltrials.gov
NCT05618925
Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06510309
Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07195799
Linperlisib Combination With Cyclophosphamide, Prednisone, and Thalidomide (CPT) in R/R NHL
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07059650
DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06504940
Optimize Study - Orelabrutinib Combined With BR/G in Untreated Marginal Zone Lymphoma (MZL)
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06558604
Phase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-risk Mantle-cell Lymphoma
正在招募
Phase 2
生物制剂
clinicaltrials.gov
NCT04586478
Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06190067
Azacitidine Plus PD-1 Therapy for R/R Hodgkin Lymphoma
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT01555892
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
正在招募
EARLY / Phase 1
药物
clinicaltrials.gov
NCT04227015
A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy
正在招募
Phase 2
药物手术/操作
clinicaltrials.gov
NCT05852717
Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma
即将招募
Phase 2, Phase 3
药物
clinicaltrials.gov
NCT07647432
HEME-25: Open-Label Feasibility Study of Elranatamab Utilized in Newly Diagnosed Plasmablastic Lymphoma With or Without HIV
即将招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07159906
Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
正在招募
Phase 2
放疗
clinicaltrials.gov
NCT07628738
A Prospective Clinical Study on Reduced-intensity Radiotherapy for Stage I/II Low-risk Nasal-type NK/T-cell Lymphoma Achieving Complete Remission After Chemotherapy
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07207785
PirtobrUtinib as Frontline Therapy for Elderly Unfit/Frail Patient With MAntle Cell Lymphoma
正在招募
Phase 1, Phase 2
生物制剂
clinicaltrials.gov
NCT07523555
Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
即将招募
Phase 1
药物
clinicaltrials.gov
NCT07032324
A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma ( CT1190B-CG1101 )
正在招募
Phase 2
生物制剂药物
clinicaltrials.gov
NCT04484012
Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06392477
A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Relapsed/ Refractory B-Cell Non-Hodgkin Lymphoma
即将招募
Phase 2
生物制剂药物手术/操作
clinicaltrials.gov
NCT07662928
Epcoritamab in Combination With Dose Adjusted EPOCH-R for High-risk Burkitt Lymphoma (BL), The BEDROCK Study
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06875063
GB5005 CART-cell Injection in the Treatment of Patients With CD19-positive RR B-NHL
正在招募
阶段未标明
药物
clinicaltrials.gov
NCT07248163
Universal CAR-T Cell Therapy for NHL
正在招募
Phase 2
药物
clinicaltrials.gov
NCT04906096
Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSL
正在招募
Phase 1
基因治疗
clinicaltrials.gov
NCT02917083
CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)
即将招募
Phase 1
生物制剂
clinicaltrials.gov
NCT07334574
Clinical Study of XP-006 mRNA Vaccine for R/R B-NHL
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07053670
A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma ( CT1190B-CG11001 )
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07082686
A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07283822
Amping up With PemJAK
即将招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07117305
CD7 CAR-T Combined With Autologous Hematopoietic Stem Cell Transplantation
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06468267
RIC With Thiotepa Combined With Bu/Flu/Ara-C in Allo-HSCT for Relapsed or Refractory PTCL.
即将招募
Phase 4
药物
clinicaltrials.gov
NCT07264894
ZSDT for the Treatment of R/R Mantle Cell Lymphoma After BTK Inhibitor Failure: a Multi-center Prospective Clinical Trial
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07372365
Orelabrutinib as Consolidation and Maintenance Therapy in Treatment-Naïve MZL.
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06848569
Sintilimab Plus AVD in Pediatric Low/Moderate Risk Hodgkin Lymphoma: A Phase II Study
正在招募
Phase 2
药物手术/操作
clinicaltrials.gov
NCT06377540
MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma
正在招募
Phase 1, Phase 2
生物制剂
clinicaltrials.gov
NCT05607420
Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06733441
A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT04068597
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07106723
Clinical Study of the Safety and Efficacy of ASCT Combined With CD7-CART in the Treatment of CD7+ TCL
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07496229
Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3)
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05768529
Clinical Study of U16 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
即将招募
EARLY / Phase 1
联合产品
clinicaltrials.gov
NCT05728879
Characterization of the Microbiome in Cutaneous T Cell Lymphoma Skin Lesions Before and After Use of APR-TD011® (RLF-TD011®) Spray Solution
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07276737
Preconditioning With a Combination of Thiotepa, Cyclophosphamide, and Busulfan for Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of NK/T-Cell Lymphoma
正在招募
Phase 2
生物制剂药物
clinicaltrials.gov
NCT04083495
CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07123454
A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
正在招募
Phase 2
生物制剂药物
clinicaltrials.gov
NCT04561206
Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06021678
Safety and Efficacy of EX103 in Subjects with Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma
正在招募
Phase 2
药物其他
clinicaltrials.gov
NCT07261163
Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell Lymphoma
即将招募
Phase 2
生物制剂
clinicaltrials.gov
NCT02497898
Treatment of CIK for Patients With Refractory Non-Hodgkin Lymphoma
即将招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06757387
Chidamide Plus Golidocitinib in Relapsed/Refractory Peripheral T-Cell Lymphoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06513234
Combination of Orelabrutinib and Obinutuzumab in Untreated Marginal Zone Lymphomas
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06150664
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06427213
This is a Phase II, Open-label, Multicentre Study of Zanubrutinib-containing Regimens in Patients With Newly Diagnosed Mantle Cell Lymphoma
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT07239323
In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies
即将招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07641010
PD-1 Antibody and JAK1 Inhibitor for Newly Diagnosed Pediatric Hodgikin's Lympoma
即将招募
Phase 1, Phase 2
生物制剂
clinicaltrials.gov
NCT07162571
This is a Phase I/II Interventional, Open-label Treatment Study Designed to Evaluate the Safety and Efficacy of Anti CD 19/22 CAR- T Cells Immunotherapy for Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia/Lymphoma.
正在招募
Phase 4
药物
clinicaltrials.gov
NCT07355699
Application of Orelabrutinib With or Without CD20 Monoclonal Antibody in Previously Untreated Marginal Zone Lymphoma
正在招募
Phase 1, Phase 2
生物制剂
clinicaltrials.gov
NCT06395103
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06573138
Selinexor, Anti-PD-1 Antibody Plus Golidocitinib in R/R NKTCL
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07199296
Orelabrutinib and Rituximab With Optional Autologous Hematopoietic Stem Cell Transplantation in MCL Treatment
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT07284927
Clinical Study of LV009 Injection for the Treatment of Hematologic and Lymphoid Malignancies
正在招募
Phase 2
药物其他
clinicaltrials.gov
NCT07209059
PET-Adapted First-Line Therapy With Nivolumab for Advanced Hodgkin Lymphoma
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06565689
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK012
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT06173518
A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06879340
Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients With Relapsed or Refractory B-cell Malignancies
正在招募
Phase 2
药物
clinicaltrials.gov
NCT02693535
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT06176690
Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas
正在招募
Phase 3
药物放疗
clinicaltrials.gov
NCT04685616
Brentuximab Vedotin in Early Stage Hodgkin Lymphoma
即将招募
Phase 2, Phase 3
药物
clinicaltrials.gov
NCT06548347
A Phase II/III Study of Linperlisib Plus CHOP Versus CHOP in Patients With Newly Diagnosed Peripheral T Cell Lymphoma
即将招募
EARLY / Phase 1
药物
clinicaltrials.gov
NCT07048353
CD30 CAR-T in the Treatment of CD30 Positive Lymphoma
即将招募
Phase 1
生物制剂
clinicaltrials.gov
NCT07679919
BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Hematologic Malignancies
正在招募
Phase 2
生物制剂器械药物
clinicaltrials.gov
NCT06252675
Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT03587844
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06776952
A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06484985
Study of AXT-1003 in Subjects With Advanced Malignant Tumors.
正在招募
Phase 2
生物制剂药物手术/操作
clinicaltrials.gov
NCT06839053
Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06534437
MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)
即将招募
Phase 1
药物
clinicaltrials.gov
NCT07661537
A Clinical Study of SHR-3079 in B-cell Non-Hodgkin Lymphoma
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06082102
Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06553872
Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL
即将招募
Phase 1
药物
clinicaltrials.gov
NCT07518329
Study of ALA-101 in Patients With CD19 Positive Non-Hodgkin Lymphoma and Leukemia.
即将招募
Phase 2
生物制剂药物
clinicaltrials.gov
NCT07569965
Frontline Risk-Adapted Optimization of Novel Targeted Immunotherapy Evaluation in High-Risk MCL
正在招募
Phase 2
药物手术/操作放疗
clinicaltrials.gov
NCT05031897
Two Step Haplo With Radiation Conditioning
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05909059
CAR T-cell Therapy in Patients With Renal Dysfunction
正在招募
Phase 1
生物制剂手术/操作
clinicaltrials.gov
NCT05801913
Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) for the Treatment of Intermediate or High Grade B-Cell Non-Hodgkin Lymphoma
正在招募
Phase 1, Phase 2
生物制剂药物
clinicaltrials.gov
NCT05702853
Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL
正在招募
Phase 2
药物
clinicaltrials.gov
NCT03739502
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
正在招募
Phase 2
药物其他
clinicaltrials.gov
NCT05346809
Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07222631
SB-4826 in Adult Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphomas
正在招募
Phase 2, Phase 3
药物
clinicaltrials.gov
NCT05770037
DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT05370430
BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL
即将招募
EARLY / Phase 1
基因治疗
clinicaltrials.gov
NCT07546630
Nanobody-Based CD19/CD20 Tandem Dual CAR-T-cell Therapy of Relapsed/Refractory B-Cell Lymphoma
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT05887167
Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies
正在招募
Phase 2
生物制剂药物手术/操作
clinicaltrials.gov
NCT05873712
Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome
即将招募
Phase 1
药物手术/操作
clinicaltrials.gov
NCT07332507
Testing the Effect of Teclistamab on Recurrent Plasmablastic Lymphoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT04378647
BREntuximab Vedotin in SEcond LIne Therapy BEfore Transplant
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06393361
Chidamide Decitabine Plus Anti-PD-1 Antibody for Patients With R/R cHL Who Are Transplant-ineligible or Refused Transplant.
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05675813
Genotype-guided Treatment in Newly Diagnosed PTCL
正在招募
阶段未标明
药物放疗
clinicaltrials.gov
NCT02797717
Treatment for Classical Hodgkin Lymphoma in Children and Adolescents
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07276698
Clinical Study on Maintenance Therapy With Selinexor Combined With Azacitidine After Allogeneic Hematopoietic Stem Cell Transplantation for NK/T-cell Lymphoma
正在招募
Phase 2, Phase 3
药物
clinicaltrials.gov
NCT06756152
Preventing of GVHD with Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Ruxolitinib At Children and Young Adults with Hemoblastosis
即将招募
Phase 1
药物
clinicaltrials.gov
NCT07192471
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
正在招募
Phase 1, Phase 2
生物制剂药物其他
clinicaltrials.gov
NCT03011814
Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma
即将招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07658352
A First-in-Human Study of HP-002 for Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
正在招募
Phase 1, Phase 2
生物制剂
clinicaltrials.gov
NCT02332668
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
正在招募
Phase 1
生物制剂药物
clinicaltrials.gov
NCT07055477
A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)
正在招募
Phase 2
药物
clinicaltrials.gov
NCT04922567
Efficacy and Safety of Lenalidomide Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07208981
Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZL
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06072131
To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06909877
Study to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell Lymphoma
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT07456371
PIC1 Injection Therapy for Relapsed/Refractory B-NHL
即将招募
Phase 1
生物制剂
clinicaltrials.gov
NCT07335328
Fully Human Bispecific Anti-CD20, Anti-CD19 CAR T Cells for Patients With Relapsed and/or Refractory B Cell Malignancies
正在招募
EARLY / Phase 1
药物
clinicaltrials.gov
NCT04532281
A Study of Murine CD19 CAR-T Therapy for Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancies
正在招募
Phase 2
生物制剂
clinicaltrials.gov
NCT07125872
Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma
正在招募
Phase 4
药物
clinicaltrials.gov
NCT07016165
Ciprofloxacin vs Ceftazidime for Empirical Treatment of High-Risk Neutropenic Fever in Children With Hematologic Malignancies
正在招募
Phase 1
药物
clinicaltrials.gov
NCT05312801
Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Non-Hodgkin Lymphoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06793189
MZL-IPI Risk-adapted Targeted Therapy in Untreated MZL
正在招募
Phase 2
药物手术/操作
clinicaltrials.gov
NCT03618550
Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
正在招募
阶段未标明
药物
clinicaltrials.gov
NCT06618313
One Trial to Evaluate the Safety, Tolerability and Efficacy of JCXH-213 in Patients With r/r B-NHL
正在招募
Phase 1
药物
clinicaltrials.gov
NCT05098613
Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients
即将招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT04856137
A Phase I/II Study of Diffuse Large B-cell Lymphoma
即将招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06845241
Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
正在招募
Phase 2
生物制剂手术/操作
clinicaltrials.gov
NCT07003295
Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy
正在招募
Phase 1, Phase 2
生物制剂药物
clinicaltrials.gov
NCT06014073
TRAC and Power3 (SPPL3) Genes Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-NHL
正在招募
Phase 3
药物
clinicaltrials.gov
NCT07414758
Golidocitinib Versus Placebo as Maintenance Therapy in PTCL Patients With Response (CR/PR) After First-Line Chemotherapy
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05996185
Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05833763
A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure.
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06420089
CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL)
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06698822
A Phase 2 Trial to Assess Safety and Efficacy of Tofacitinib 2% Cream in the Treatment of Cutaneous T-cell Lymphoma (CTCL), Stages IA, IB, and IIA
即将招募
Phase 2
其他放疗
clinicaltrials.gov
NCT07517705
MRD-Adapted Low-Dose Radiation Therapy During Frontline Chemoimmunotherapy for Diffuse Large B-Cell Lymphoma
即将招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05091541
A Phase 1/2 Study of CT120 in Patient With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05180097
Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06589089
Autologous Hematopoietic Stem Cell Boost Study After CAR-T Therapy
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07502872
TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma
正在招募
Phase 2
生物制剂其他手术/操作
clinicaltrials.gov
NCT06238648
Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy
即将招募
阶段未标明
药物
clinicaltrials.gov
NCT07542912
Sintilimab, Chidamide, and Azacitidine for Untreated Stage I-II Extranodal NK/T-Cell Lymphoma
正在招募
Phase 1
生物制剂药物
clinicaltrials.gov
NCT06251180
Phase Ib Study of Rocbrutinib in Combination With R-CHOP in Patients With Newly Diagnosed B-cell Non-Hodgkin Lymphoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06854003
BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06244368
GVM±R in Patients With Relapsed or Refractory Aggressive NHL.
正在招募
阶段未标明
药物
clinicaltrials.gov
NCT06890065
JY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ Leukemia
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT03523975
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05842707
Study of Cord Blood-derived CAR NK Cells Targeting CD19/CD70 in Refractory/Relapsed B-cell Non-Hodgkin Lymphoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06854445
Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06363994
A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL
正在招募
Phase 1, Phase 2
生物制剂
clinicaltrials.gov
NCT02259556
CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06271057
Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse
正在招募
Phase 1
生物制剂放疗
clinicaltrials.gov
NCT05967416
Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06656221
A Prospective, Single-Center Study Evaluating the Efficacy and Safety of Glofitamab Combined With Orelabrutinib and Bortezomib in Patients With High-Risk Mantle Cell Lymphoma
正在招募
阶段未标明
药物
clinicaltrials.gov
NCT06783816
A Novel CAR-T Combined Expression of IL-15 in the Treatment of Malignant Hematological Tumors
即将招募
Phase 3
生物制剂药物
clinicaltrials.gov
NCT05700448
Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma
即将招募
Phase 2
器械药物手术/操作
clinicaltrials.gov
NCT07021989
ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07234487
Comparison of AVD + Low-Dose Nivolumab vs. PET-Adapted BEACOPP-like in Advanced cHL
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07002216
BrECADD Therapy in Stage 2 B-IV Hodgkin Lymphoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT04915248
Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients.
正在招募
Phase 1
药物手术/操作
clinicaltrials.gov
NCT05773040
A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06911710
The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors
正在招募
EARLY / Phase 1
生物制剂
clinicaltrials.gov
NCT04662294
CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07081022
JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06742996
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07188090
Mozobil for Autologous Hematopoietic Stem Cell Transplantation
正在招募
Phase 1, Phase 2
生物制剂
clinicaltrials.gov
NCT03765177
CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies
正在招募
阶段未标明
药物
clinicaltrials.gov
NCT06069830
PET and EBV DNA-directed Therapy for Localized Nasal Extranodal NK/T Cell Lymphoma
正在招募
Phase 2
药物放疗
clinicaltrials.gov
NCT04128072
Anti-CCR4 Monoclonal Antibody (Mogamulizumab) and Total Skin Electron Beam Therapy (TSEB) in Patients With Stage IB-IIB Cutaneous T-Cell Lymphoma
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT07620314
Safety and Efficacy of KSVCBD Injection in B-cell Non-Hodgkin's Lymphoma Expressing CD19 and/or BCMA
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05615636
A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06700798
Orelabrutinib Combined With Rituximab Versus R-CVP in the Untreated MZL： A Randomized, Open Phase II Trial
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06734871
A Clinical Study Exploring CT1190B in the Treatment of Patients with Relapsed/refractory B-cell Non-Hodgkin Lymphoma
正在招募
Phase 1
药物
clinicaltrials.gov
NCT05476770
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
正在招募
阶段未标明
生物制剂
clinicaltrials.gov
NCT06866873
CD-19 CAR-T Cell for Pediatric ALL or Lymphoma
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06820268
A Study of XS-04 in Patients with Relapsed or Refractory Hematologic Malignancies
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT03161223
Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma
即将招募
Phase 1
生物制剂
clinicaltrials.gov
NCT07616089
Phase I Study of FXS0683 in the Treatment of Blood Tumors
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT07164560
Exploratory Study of Umbilical Cord Blood-Derived CAR-NK Cell Therapy Targeting TRBC1/2 for Relapsed/Refractory T-Cell Lymphoma
正在招募
Phase 2
生物制剂药物手术/操作
clinicaltrials.gov
NCT06059391
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06697184
A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
即将招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07288814
Mitoxantrone Hydrochloride Liposome and Enlonstobart Combination Treatment in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL)
正在招募
Phase 1, Phase 2
生物制剂药物
clinicaltrials.gov
NCT06838832
Novel Allogenic CD19-targeting CAR-γδT Cell Therapy (QH103E) in r/r NHL
正在招募
阶段未标明
药物
clinicaltrials.gov
NCT06850285
CD30 CAR-T in the Treatment of CD30 Positive Relapsed/Refractory Lymphoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06756308
A Study of Enasidenib in People With T-Cell Lymphoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06151106
Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma
正在招募
Phase 2
生物制剂药物
clinicaltrials.gov
NCT05260957
CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL).
即将招募
Phase 2
药物放疗
clinicaltrials.gov
NCT06646666
ARTA-based Chemo-free Bridging/Maintenance Therapy in CAR-T Treatment for High-Risk R/R B-NHL Ineligible for HDCT and ASCT
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05949931
Pianzumab Combined With AVD Regimen in the Treatment of Newly-diagnosed Advanced Classic Hodgkin Lymphoma
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07093710
Golidocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma
即将招募
Phase 2
药物
clinicaltrials.gov
NCT04913103
Study of PV in Combination With Bendamustine and Rituximab for Patients With R/R MCL
正在招募
EARLY / Phase 1
生物制剂
clinicaltrials.gov
NCT06446128
A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed or Refractory B Cell Non-Hodgkin Lymphoma(NHL)
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT06503211
On the Safety, Tolerability, and Efficacy of UTAA09 Injection in the Treatment of Lymphoma
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07206264
Chemotherapy Combined With Targeted Therapy as First-line Treatment for Mantle Cell Lymphoma Based on MRD and PET-CT Assessment
正在招募
Phase 2
生物制剂放疗
clinicaltrials.gov
NCT06104592
Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL
正在招募
Phase 2
生物制剂
clinicaltrials.gov
NCT05648019
CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol
即将招募
Phase 3
药物手术/操作
clinicaltrials.gov
NCT07678229
BRIDGE-NK: Immunotherapy Versus Chemotherapy Induction Followed by Autologous HSCT in Advanced NKTCL
即将招募
Phase 1
药物
clinicaltrials.gov
NCT06712173
Linperlisib Combined With EZH2 Inhibitor in Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL)
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07453095
Study With Glofitamab in Patients With MCL and Inadequate Response or Relapse Following CAR T-cell Therapy
正在招募
Phase 1
药物
clinicaltrials.gov
NCT05054257
CART19 Cells Effects in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT06208735
CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT07369492
Safety and Efficacy Study of BAFF-R CAR-T Cells in Adult Subjects With CD19-Negative Relapsed or Refractory B-Cell Lymphoma
正在招募
Phase 2
诊断检测药物
clinicaltrials.gov
NCT06377566
A Study of BV-AVD in People With Bulky Hodgkin Lymphoma
正在招募
Phase 1
生物制剂药物
clinicaltrials.gov
NCT07052305
NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma
正在招募
EARLY / Phase 1
药物
clinicaltrials.gov
NCT03719105
Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05800366
A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05956041
Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas
正在招募
EARLY / Phase 1
药物
clinicaltrials.gov
NCT07101705
An Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection in Treating Relapsed/Refractory Hematological Malignancies
正在招募
Phase 2
生物制剂药物
clinicaltrials.gov
NCT06486051
A Study of WZTL-002 CAR T-cells for Adults With Relapsed Large B-cell Lymphoma
正在招募
EARLY / Phase 1
药物
clinicaltrials.gov
NCT06693973
An Early Clinical Study Evaluating the Safety and Efficacy of AcNK-Sup003 Cell Injection in the Treatment of Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07093073
Clinical Study of U01（ssCART-19） in Patients With B-Cell Lymphoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05296070
Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT04544592
UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06029309
Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma
即将招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07520006
Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
正在招募
Phase 2
药物
clinicaltrials.gov
NCT04728893
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06914037
A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies
即将招募
Phase 3
药物
clinicaltrials.gov
NCT06953739
A Study Comparing of P-GEMD Regimen Versus P-Gemox Regimen With Untreated Early-Stage NUAT or Advanced-Stage ENKTL.
正在招募
Phase 1, Phase 2
生物制剂药物其他
clinicaltrials.gov
NCT01371630
Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia
即将招募
Phase 2
生物制剂药物
clinicaltrials.gov
NCT07477366
Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma
即将招募
阶段未标明
药物
clinicaltrials.gov
NCT07345741
Clinical Study on the Safety and Efficacy of CD20/CD19 Cell Injection in the Treatment of Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06646211
High-dose Methotrexate Combined with Thiotepa and Zanubrutinib in the Treatment of Newly Diagnosed PCNSL (MTZ)
正在招募
Phase 2
药物
clinicaltrials.gov
NCT04496349
A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06462248
Anti-CD19 Chimeric Antigen Receptor Modified T-cell (CAR-T) Therapy for Treatment of B-cell Hematological Malignancies
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05623982
A Study of GNC-038 Injection in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
正在招募
Phase 2
生物制剂药物其他
clinicaltrials.gov
NCT02877303
Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT06037018
Safety Study of CC312 in Adult Patients With Relapsed/Refractory CD19 Positive B-cell Hematologic Malignancies
正在招募
Phase 1
药物
clinicaltrials.gov
NCT04993690
A Study of LP-168 in Participants With Relapse or Refractory B-Cell Lymphoma
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07684950
Lisaftoclax Plus Pirtobrutinib in Relapsed or Refractory Mantle Cell Lymphoma After BTK-Targeted Therapy
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06213311
A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma
正在招募
Phase 1, Phase 2
药物其他
clinicaltrials.gov
NCT07284433
Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
正在招募
阶段未标明
药物
clinicaltrials.gov
NCT07211048
Anti CD19 Gene Therapy for B-cell Lymphoma
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT07398963
Clinical Study of Oncolytic Vaccinia VIrus Delivering Targeted CD19 in Vivo CAR-T/M Therapy for Refractory/Relapsed B-cell Lymphoma
正在招募
EARLY / Phase 1
器械药物
clinicaltrials.gov
NCT06398457
Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07013565
Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL
正在招募
阶段未标明
药物手术/操作
clinicaltrials.gov
NCT07072221
Bendamustine Combined With Chidamide and Lenalidomide for Relapsed and Refractory PTCL Patients
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT06227026
Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed/Refractory CD19+ Malignancies
正在招募
Phase 1, Phase 2
生物制剂
clinicaltrials.gov
NCT06987916
Efficacy and Safety Evaluation of U01(ssCART-19) in B-Cell Lymphoma
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT04288726
Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas
即将招募
EARLY / Phase 1
基因治疗
clinicaltrials.gov
NCT06097455
First in Human Study of the Infusion of ARI0003 Cells in Relapsed/Refractory to Treatment B-cell Aggressive Lymphoma
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06855823
A Phase I/II Study of Golidocitinib Combined with Pomalidomide in R/R PTCL
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06984146
Nivo40-AVD for Advanced Classic Hodgkin Lymphoma
即将招募
EARLY / Phase 1
生物制剂
clinicaltrials.gov
NCT07563023
Exploratory Study on the Treatment of EB Virus Positive HIV Associated Lymphoma With EBV mRNA Vaccine
正在招募
Phase 2, Phase 3
生物制剂药物
clinicaltrials.gov
NCT07202052
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial (RATIONAL-PT)
正在招募
Phase 2
器械药物
clinicaltrials.gov
NCT05680558
Photopheresis in Early-stage Mycosis Fungoides
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06634589
A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05846750
Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Marginal Zone Lymphoma
正在招募
Phase 1
药物手术/操作
clinicaltrials.gov
NCT06223542
Studying TAK-243 in Patients With Advanced Cancer
正在招募
EARLY / Phase 1
药物
clinicaltrials.gov
NCT07376642
A Phase I/IIa, Open-label, Single-center, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IMV101 as a Single Agent in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
正在招募
Phase 2
生物制剂药物
clinicaltrials.gov
NCT04626791
Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05463263
A Phase 1/2 Study of STP938 (Dencatistat) for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas
正在招募
Phase 1, Phase 2
生物制剂药物
clinicaltrials.gov
NCT06323525
TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05868395
Efficacy of Polatuzumab, Bendamustine and Rituximab in Patients With Relapsed/ Refractory Mantle Cell Lymphoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06630091
A Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of Newly Diagnosed Peripheral T Cell Lymphoma Patients (GOLDEN Study) and Correlative Study
正在招募
Phase 1
药物
clinicaltrials.gov
NCT05544968
Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies
正在招募
Phase 4
药物
clinicaltrials.gov
NCT05806580
Secondary Infusion of Relma-cel Injection for Relapsed or Refractory B-cell Lymphoma
正在招募
Phase 2
生物制剂药物
clinicaltrials.gov
NCT07341191
Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05436223
Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma
即将招募
Phase 1
生物制剂药物手术/操作
clinicaltrials.gov
NCT07676877
Lymphodepletion With Low Dose Total Body Irradiation Before Standard of Care Tisagenlecleucel for the Treatment of Relapsed and Recurrent Large B-cell Lymphoma
正在招募
Phase 2
生物制剂药物放疗
clinicaltrials.gov
NCT07566377
Cord Blood Transplantation in Children and Young Adults With Blood Cancer
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06699771
Phase 1 to Investigate the Safety, Tolerability, and Efficacy of GCC2005 in Patients With R/R NK and T-cell Malignancies
正在招募
Phase 2
药物
clinicaltrials.gov
NCT03852407
Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning
正在招募
Phase 2
生物制剂药物手术/操作
clinicaltrials.gov
NCT06723457
Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymphoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06566586
A Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT04837859
Phase II Trial of Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin Lymphoma
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06702605
To Evaluate XNW5004 Tablets in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma
即将招募
Phase 3
生物制剂药物
clinicaltrials.gov
NCT06465446
A Study of IMM01 Plus Tiselizumab Versus Physician's Choice Chemotherapy in PD(L)1-refractory Classical Hodgkin Lymphoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07285590
Clinical Trial to Evaluate the Efficacy and Safety of Pirtobrutinib With Rituximab in Patients With Mantle Cell Lymphoma
正在招募
EARLY / Phase 1
药物
clinicaltrials.gov
NCT04532268
A Study of Humanized CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell ALL and B-cell NHL
正在招募
Phase 2
生物制剂
clinicaltrials.gov
NCT06534060
MB-105 in Patients With CD5 Positive T-cell Lymphoma
正在招募
EARLY / Phase 1
生物制剂
clinicaltrials.gov
NCT07205315
A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06547528
A Phase I Study to Investigate the Tolerability and Safety of ONO-4685 Given as Monotherapy in T Cell Lymphoma and CLL/SLL
正在招募
Phase 1
生物制剂药物手术/操作
clinicaltrials.gov
NCT04892277
CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06554600
A Study of Zanubrutinib in Combination With Polatuzumab Vedotin, Bendamustine and Rituximab in the Treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma
正在招募
Phase 1, Phase 2
生物制剂
clinicaltrials.gov
NCT06101381
CD19-directed CAR-T Cell Therapy for R/R Acute Leukemia and Lymphoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05976997
Prospective, Single Arm, Single Center Study of Duvelisib Combined With Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma (PTCL)
正在招募
Phase 1, Phase 2
生物制剂药物手术/操作
clinicaltrials.gov
NCT06249191
Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma
正在招募
Phase 1
药物手术/操作
clinicaltrials.gov
NCT06675123
Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06454968
Orelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Zone Lymphoma.
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06986174
A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia
正在招募
Phase 4
药物
clinicaltrials.gov
NCT06876662
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06219356
A Study of GLB-002 in Patients With Relapsed or Refractory Non-Hodgkin Lymphomas
正在招募
Phase 2
生物制剂药物
clinicaltrials.gov
NCT03136146
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07673367
Nemtabrutinib With CAR T Therapy in Relapsed/Refractory Mantle Cell Lymphoma
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06119685
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07047885
Ropeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTCL)
即将招募
Phase 3
药物
clinicaltrials.gov
NCT07639879
TR115 VS Investigator's Choice in Relapsed/Refractory Peripheral T/NK Cell Lymphoma
正在招募
Phase 1
药物
clinicaltrials.gov
NCT05362773
A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies
正在招募
Phase 1
药物
clinicaltrials.gov
NCT05010005
A Study of Ruxolitinib and Duvelisib in People With Lymphoma
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07283679
Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma
即将招募
Phase 2
生物制剂药物
clinicaltrials.gov
NCT07622784
Pirtobrutinib Maintenance After CAR-T Therapy in Relapsed or Refractory B-Cell Lymphoma
正在招募
Phase 3
联合产品药物
clinicaltrials.gov
NCT06520163
Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT04752826
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05908409
A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06137144
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05833893
Clinical Study of XPO1 Inhibitor Selinexor Combined With COPL in Newly Diagnosed Advanced NK/T-cell Lymphoma
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07220616
A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies
正在招募
Phase 2, Phase 3
生物制剂药物
clinicaltrials.gov
NCT07202078
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Starting Immunoglobulin (Start Ig)
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06716658
JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas
正在招募
Phase 2
生物制剂药物手术/操作
clinicaltrials.gov
NCT02981628
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
正在招募
Phase 1, Phase 2
生物制剂药物
clinicaltrials.gov
NCT05554939
Allogenic CD19-targeting CAR-γδT Cell Therapy in R/R NHL
正在招募
Phase 1
药物
clinicaltrials.gov
NCT05892718
A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors
正在招募
Phase 2
生物制剂药物手术/操作
clinicaltrials.gov
NCT06572618
Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell Lymphoma
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07308132
A Study of JNJ-95566692 in Participants With Non-Hodgkin Lymphoid Malignancies
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06482684
CAR-T-cell Treatment for Untreated High Risk MANtle Cell Lymphoma
正在招募
Phase 1
药物
clinicaltrials.gov
NCT05341557
A Phase 1 Study of BPI-371153 in Subjects with Advanced Solid Tumors or Relapsed/Refractory Lymphoma
正在招募
Phase 3
药物
clinicaltrials.gov
NCT07342478
ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
正在招募
Phase 2
药物手术/操作放疗
clinicaltrials.gov
NCT05681195
Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07416890
Thiotepa in Combination With Pirtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1 Inhibitor) for Frail or Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma
正在招募
Phase 2
生物制剂
clinicaltrials.gov
NCT07538635
CAR-T Combined With ASCT in the Treatment of Relapsed/Refractory Large B-cell Lymphoma With High-risk Factors.
正在招募
Phase 1, Phase 2
生物制剂
clinicaltrials.gov
NCT05800977
A Study of C-CAR039 (Prizloncabtagene Autoleucel) in Patients With Relapsed/Refractory Large B-Cell Lymphoma
正在招募
Phase 1, Phase 2
药物手术/操作
clinicaltrials.gov
NCT04870944
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06207123
A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05147467
Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07599423
A Study of Glofitamab Plus GemOx Compared With Standard of Care in Patients With Relapsed/Refractory Large B-Cell Lymphoma
即将招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07447726
Exploratory Clinical Study on the Safety and Efficacy of CD19X CAR-T Cell Injection in the Treatment of Relapsed/Refractory Large B-Cell Lymphoma
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT07044050
A First-in-human Study to Assess OT-C001 (Amplified/Activated Allogenic Natural Killer Cells) in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05891821
Assessment of the Safety and Efficacy of Balstilimab for the Treatment of Relapsed/Refractory Lymphomas (IMMONC0001)
正在招募
Phase 2
药物
clinicaltrials.gov
NCT02974647
Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma
即将招募
Phase 2
生物制剂药物
clinicaltrials.gov
NCT06567366
CAR T-cell Therapy in Combination With Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma With High-Risk Prognostic Factors
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06376721
Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma
即将招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07476066
Clinical Study of SYS6055 Injection in Participants With Relapsed/Refractory Aggressive B-Cell Lymphoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06788964
Loncastuximab Tesirine and Rituximab as Bridging Therapy Before Standard-of-care CAR-T Therapy in Patients With Large B-cell Lymphoma (CORAL)
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT07137494
A Study of MB-CART19.1 Cellular Therapy for People With Central Nervous System Lymphoma (CNSL)
即将招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07441954
Pomalidomide Combined With Obinutuzumab in the Treatment of Patients With Relapsed/Refractory Indolent Lymphoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06876688
Relma-cel Followed by Tislelizumab for the Treatment of Relapsed/Refractory CNS Large B-Cell Lymphoma
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06966154
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT07108868
A Phase I Dose Finding Study of MB-CART2219.1
即将招募
EARLY / Phase 1
生物制剂
clinicaltrials.gov
NCT07670260
GoFast CAR T-Cell Therapy for Recurrent Refractory B-Cell Lymphoma
正在招募
EARLY / Phase 1
生物制剂
clinicaltrials.gov
NCT07131254
A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in Adult Participants With Relapsed/Refractory CD19-positive B-cell Malignant Hematological Tumors
正在招募
Phase 2
药物手术/操作
clinicaltrials.gov
NCT07061951
Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia
正在招募
阶段未标明
生物制剂
clinicaltrials.gov
NCT05626400
Clinical Study of Senl-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ Acute T-ALL/T-LBL
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06737250
NB02 (Poseltinib) Combined Rituximab and Lenalidomide in R/R PCNSL
正在招募
Phase 2
生物制剂药物
clinicaltrials.gov
NCT07194980
Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT06909474
Clinical Trial of CD5-targeted CAR-NK Therapy for Relapse/Refractory T-Cell Hematologic Malignancies
正在招募
Phase 2
药物手术/操作
clinicaltrials.gov
NCT05934448
Pembro Plus CAR T-cell Therapy in R/R in PMBCL
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06561074
A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy)
即将招募
Phase 1
生物制剂
clinicaltrials.gov
NCT07623681
Single-arm, Open-label, Dose-escalating Phase I Clinical Study of PA3-17 Injection in Children and Adolescents With Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05698147
Selinexor in Combination With MTX+Ritu to Treat R/R CNSL
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT06709469
Phase I Clinical Trial of CART Cell Therapy for Refractory/Relapsed Acute Lymphoblastic Leukemia in Children, Adolescents and Young Adults
正在招募
Phase 3
药物
clinicaltrials.gov
NCT07139873
A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)
即将招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07139353
Linperlisib Combined With Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT04560322
Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL
即将招募
Phase 1, Phase 2
联合产品
clinicaltrials.gov
NCT05909098
Safety and Efficacy of Autologous NK Cell Adjuvant Therapy for Relapsed/Refractory Non-Hodgkin's B-cell Lymphoma
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06943872
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
正在招募
Phase 1, Phase 2
生物制剂
clinicaltrials.gov
NCT05948033
CD70 Targeted CAR-T Cells in CD70 Positive Relapsed/Refractory Lymphoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06588478
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
正在招募
Phase 1, Phase 2
生物制剂
clinicaltrials.gov
NCT07153068
SupCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06793956
Sintilimab and Linperlisib Combination Treatment in Relapsed or Refractory Extranodal Natural Killer/T Cell Lymphoma
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06624085
A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07221500
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06615193
A Study of HDM2005 in Patients With Relapsed/Refractory B-cell Lymphoma and Advanced Solid Tumor
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05745714
HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT05679895
Safety and Efficacy of OC-1 Therapy in Patients With R/R T-ALL/LL
正在招募
Phase 1
药物
clinicaltrials.gov
NCT05292664
Venetoclax Basket Trial for High Risk Hematologic Malignancies
即将招募
Phase 1
药物
clinicaltrials.gov
NCT07511426
U96-CAR-T-Cells For R/R B-ALL
正在招募
Phase 2
药物
clinicaltrials.gov
NCT02966756
A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
即将招募
Phase 1
生物制剂
clinicaltrials.gov
NCT07316907
A Clinical Study of Allogenic CD19-CAR-T in the Treatment of R/R B-Cell Hematologic Malignancies
正在招募
阶段未标明
药物
clinicaltrials.gov
NCT06689917
JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT04421560
Pembrolizumab, Ibrutinib and Rituximab in PCNSL
正在招募
Phase 2
生物制剂
clinicaltrials.gov
NCT06514794
A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)
正在招募
EARLY / Phase 1
药物
clinicaltrials.gov
NCT07598578
An Open-label, Single-arm, Multicenter Phase II Clinical Study of Azacitidine, Chidamide Combined With PD-1 Monoclonal Antibody in the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma.
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05658640
HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07018752
A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral T-cell Lymphomas
正在招募
EARLY / Phase 1
生物制剂
clinicaltrials.gov
NCT07344818
An Open and Dose-escalation Early Clinical Study of CD19 and CD20 CAR-T Cell Therapy for Relapsed or Refractory Aggressive B-cell Lymphoma
正在招募
Phase 1
生物制剂手术/操作
clinicaltrials.gov
NCT06672705
Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative Disorders
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07240194
The Efficacy and Safety of Glofitamab in Combination With PD-1 Antibody and Lenalidomide in Patients With Relapsed/Refractory Large B-cell Lymphoma (LBCL) With TP53 Aberrations: A Prospective, Multicenter, Phase II Clinical Study
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06489808
Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCL
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT07109518
uCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies
正在招募
Phase 1
药物
clinicaltrials.gov
NCT05607498
First in Human Study of EMB-07 in Locally Advanced/Metastatic Solid Tumors or Relapse/Refractory Lymphoma
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06973187
A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07321301
Polymer-lipid Particle-delivered CAR1920 mRNA CAR-T Therapy for Relapsed/Refractory B-cell Lymphoma/Leukemia
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05931328
The Study of the Combination of Thiotepa and Pomalidomide for the Treatment of Relapsed/Refractory Primary Central Nervous System Lymphoma Patients.
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06742463
VHAG in Treating R/R T-ALL/LBL
即将招募
阶段未标明
生物制剂
clinicaltrials.gov
NCT07008872
CD7 CAR-T Cell Therapy Targeting CD7-positive Relapsed/Refractory T Cell Lymphoma/Acute Leukemia
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05751044
HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06084936
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07586618
First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Hard-to-treat Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, Focused on Safety and How the Drug Behaves in the Body and Early Signs of Effect.
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT04494503
Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL
正在招募
Phase 1
生物制剂药物
clinicaltrials.gov
NCT05631886
Combination of CAR-DC Vaccine and ICIs in Malignant Tumors
正在招募
Phase 1
生物制剂药物
clinicaltrials.gov
NCT05963217
Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06708897
A Phase 1 Study of ZE50-0134 in Relapsed and Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Select Low-grad Lymphomas
正在招募
Phase 3
药物
clinicaltrials.gov
NCT07479797
Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy
正在招募
Phase 1
药物
clinicaltrials.gov
NCT05091424
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07184788
G-Pola-GemOx in Refractory/Relapsed Aggressive B-Cell Lymphoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07024706
Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07513129
Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic Lymphoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07372352
Zeprumetostat, Azacitidine Combined With Lipo-MIT in R/R PTCL
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT04162353
BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma
即将招募
EARLY / Phase 1
药物基因治疗
clinicaltrials.gov
NCT06986434
CAR19BCMA CAR-T Cells for the Treatment of R/R Plasma Cell Neoplasms and Lymphomas/Leukemias With Plasmacytic Differentiation
正在招募
Phase 1, Phase 2
药物手术/操作
clinicaltrials.gov
NCT04315324
Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)
即将招募
Phase 1
生物制剂
clinicaltrials.gov
NCT07383233
CD19/BAFF-R in Vivo CAR-T Cell Therapy Targeting Relapsed/Refractory B Cell Acute Leukemia/Malignant Lymphoma
正在招募
阶段未标明
药物手术/操作放疗
clinicaltrials.gov
NCT07074470
Combination Regimen of Teniposide, PD-1 Monoclonal Antibody and Selinixor for Patients With Relapsed or Refractory PCNSL
即将招募
Phase 1, Phase 2
器械药物
clinicaltrials.gov
NCT07175415
HEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
即将招募
Phase 2
生物制剂药物
clinicaltrials.gov
NCT07613788
Rimegepant Plus Glofitamab and CD19 CAR-T Therapy in R/R LBCL
即将招募
EARLY / Phase 1
生物制剂
clinicaltrials.gov
NCT06519344
An Exploratory Clinical Study Evaluating the Safety and Efficacy of Intravenous Anti-CD20/CD30-CAR-T Cell Infusion in Relapsed/Refractory Lymphoma Patients.
正在招募
Phase 1, Phase 2
生物制剂药物
clinicaltrials.gov
NCT04989803
Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma
正在招募
阶段未标明
药物
clinicaltrials.gov
NCT07191431
A Clinical Study on the Efficacy and Safety of Methotrexate (MTX) or Thiotepa (for MTX Intolerance) or Temozolomide (TMZ) Combined With Orelabrutinib and Selinexor in Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma（SELINA）
即将招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05055791
A Study to Evaluate the Safety and Tolerance of SYHX1903 in Patients With Relapsed/Refractory Hematologic Malignancies
即将招募
Phase 2
生物制剂
clinicaltrials.gov
NCT07244380
Phase II Trial of S101 Autologous Anti-CD7 CAR-T Cells in Patients With R/R T-LBL/ALL.
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06733051
Phase II Study of Golidocitinib and Benmelstobart in Patients with R/R ENKTL (JACKPOT50)
正在招募
Phase 1
生物制剂药物
clinicaltrials.gov
NCT05705570
Clinical Trial Using CAR- T Cells for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid Malignancies
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07350863
U69-CART-Cells For R/R T-ALL
正在招募
EARLY / Phase 1
药物
clinicaltrials.gov
NCT07606937
A Study of Automated Axicabtagene Ciloleucel for R/R Large B-cell Lymphoma.
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06810778
Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07609823
A Study of Lacutoclax (LP-108) in Patients With Relapsed/Refractory CLL/SLL
正在招募
Phase 1, Phase 2
生物制剂药物
clinicaltrials.gov
NCT06883526
Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma
正在招募
Phase 2
生物制剂
clinicaltrials.gov
NCT07188610
PA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06916767
Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06712121
Venetoclax and Decitabine in R/R T-ALL
即将招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07107204
A Clinical Study of BT02 in Patients With Relapsed or Refractory Hematologic Malignancies
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06495723
Polyspecific Antibodies in Lymphoproliferative T-cell Disorders
正在招募
Phase 3
生物制剂药物
clinicaltrials.gov
NCT05947851
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
正在招募
EARLY / Phase 1
药物基因治疗
clinicaltrials.gov
NCT06532643
Safety and Efficacy of Anti-CD20/CD30 CAR-T Cells in Subjects with Relapsed/Refractory Lymphoma
正在招募
Phase 1
药物基因治疗
clinicaltrials.gov
NCT06743503
UB-VV400 in Combination With Rapamycin in Relapsed or Refractory B-cell Malignancies
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06919939
Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT06136364
CD7 CAR-T in Adults With Relapsed or Refractory T-LBL/ALL Clinical Study
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06573151
Selinexor, Anti-PD-1 Antibody and P-GemOx Regimen in R/R NKTCL
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06996132
Bispecific Antibody-Based Salvage Therapy Followed by CAR-T ± ASCT in R/R Aggressive B-Cell Lymphoma
正在招募
Phase 3
药物
clinicaltrials.gov
NCT07104032
IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06931652
Study of Epcoritamab in R/R Primary Diffuse Large B-cell Lymphoma of the CNS Treated With Lenalidomide and Rituximab
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05209620
Orelabrutinib Combined With Pemetrexed For Relapsed/Refractory Central Nervous System Lymphoma
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06122389
SHR2554 Clinical Study of Chidamide in the Treatment of T-cell Lymphoma
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07070219
A Study of CTD402 in T-ALL/LBL Patients
正在招募
Phase 1, Phase 2
生物制剂
clinicaltrials.gov
NCT06880913
Nanobody-Based CD19/CD22 Tandem Dual CAR-T Therapy for R/R B-ALL
正在招募
Phase 1
器械药物
clinicaltrials.gov
NCT07257419
CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma
正在招募
EARLY / Phase 1
药物
clinicaltrials.gov
NCT06307600
The Safety and Efficacy of RD06-03 CART Cell Injection in Patients With R/R Acute B-lymphoblastic Leukemia
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07082868
A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06678659
A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06563505
A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone Lymphoma
即将招募
Phase 1, Phase 2
生物制剂
clinicaltrials.gov
NCT07678307
A Multicenter, Open-label, Non-randomized, Single-arm Phase 1/2 Study of Autologous Nano CD5-CAR T Cells for the Treatment of Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06556199
A Study of Selinexor in Combination With Temozolomide and Anti-PD-1 Antibody in Patients With Relapsed/Refractory Primary Central Nervous System Lymphoma
正在招募
EARLY / Phase 1
生物制剂药物
clinicaltrials.gov
NCT06756321
A Study of CAR T-Cells in Relapsed/Refractory Hematologic Malignancy
正在招募
EARLY / Phase 1
生物制剂
clinicaltrials.gov
NCT06765876
CART123 T Cells in Relapsed or Refractory CD123+ Hematologic Malignancies: A Dose Escalation Phase I Trial
即将招募
Phase 1
药物
clinicaltrials.gov
NCT07608731
Golcadomide With Pemetrexed, Rituximab, and Dexamethasone for Relapsed and Refractory CNS Lymphomas
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06539182
DZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8)
正在招募
Phase 1, Phase 2
生物制剂
clinicaltrials.gov
NCT06064903
CD7-CAR-T Cells in Pediatric Relapsed/Refractory CD7+ T-ALL/LL
即将招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06979076
A Phase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients With Refractory or Relapsed CLL/SLL
正在招募
阶段未标明
药物
clinicaltrials.gov
NCT06678282
JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia
即将招募
阶段未标明
药物
clinicaltrials.gov
NCT06935136
Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel Injection as First-Line Therapy of High-Risk Large B-Cell Lymphoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06167785
A Study to Evaluate Zanubrutinib and Tislelizumab in Progressive Lymphoma Post CAR-T
正在招募
EARLY / Phase 1
生物制剂
clinicaltrials.gov
NCT06633341
Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-lymphoma
正在招募
阶段未标明
生物制剂
clinicaltrials.gov
NCT05618041
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
正在招募
Phase 2
药物
clinicaltrials.gov
NCT04661020
CD19 CAR-T Therapy for Patients With Newly Diagnosed High-risk Large B-cell Lymphoma
正在招募
Phase 1
生物制剂药物手术/操作
clinicaltrials.gov
NCT05625594
Intracerebroventricular Administration of CD19-CAR T Cells (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/Mem T-lymphocytes) for the Treatment of Central Nervous System Lymphoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06430736
PRONTO Trial (PRophylactic Versus ON-demand Use of TOcilizumab)
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06326463
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
即将招募
Phase 2
联合产品药物
clinicaltrials.gov
NCT07602322
LME-Guided Precision Combination Therapy in B-cell Lymphoma Patients After CD19 CAR-T Failure
正在招募
Phase 1, Phase 2
生物制剂药物
clinicaltrials.gov
NCT06364423
Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias
正在招募
阶段未标明
生物制剂
clinicaltrials.gov
NCT07509450
Fecal Microbiota Transplantation in Patients Undergoing Chimeric Antigen Receptor T-cell Therapy and Allogeneic Stem Cell Transplant: A Pilot Study
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05464719
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06071871
A Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab As a Peri-CAR-T Cell Treatment Strategy in Large B-cell Lymphoma
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT07300683
Anti-CCR9 CAR T Cells for T Cell Leukaemia/Lymphoma
即将招募
EARLY / Phase 1
生物制剂
clinicaltrials.gov
NCT07335094
A Clinical Study of Humanized CD19 CAR-T Cells With TLR2 for the Treatment of Adult Patients With Naive B-Cell Acute Lymphoblastic Leukemia/Lymphoma Who Are Intolerant to Intensive Chemotherapy
即将招募
EARLY / Phase 1
生物制剂
clinicaltrials.gov
NCT07476027
Efficacy and Safety of CD7 CAR-T in Newly Diagnosed High-Risk T-LBL/ALL
即将招募
Phase 1
生物制剂
clinicaltrials.gov
NCT07297160
CD70.CAR for CD70+ Lymphoma, Myeloma and Solid Tumors
正在招募
Phase 1, Phase 2
生物制剂
clinicaltrials.gov
NCT04033302
Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies
即将招募
Phase 1
生物制剂
clinicaltrials.gov
NCT06647329
CAR-T Technology for Recurrent/Refractory Malignant Hematological and Lymphatic Tumors
即将招募
Phase 1
生物制剂
clinicaltrials.gov
NCT07443137
CAR-T ceLL for Eradication of Active Residual Disease in LBCL (CLEAR-1 Study)
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT05995028
Universal 4SCAR7U Targeting CD7-positive Malignancies
正在招募
阶段未标明
生物制剂
clinicaltrials.gov
NCT05620680
CD7 CAR-T Cells in T-cell Lymphoma/Leukemia
第 1 页
没有符合当前筛选条件的试验。
Subtypes
建议拆分方向
DLBCLfollicular lymphomaHodgkin lymphomamantle cell lymphomarelapsed refractory lymphomaCAR-Tbispecific antibodyCD19CD20
Keyword guide
这些关键词怎么理解
| 术语 | 中文意思 | 对找临床试验有什么用 |
|---|---|---|
| DLBCL | 弥漫大 B 细胞淋巴瘤，是常见非霍奇金淋巴瘤类型。 | 很多 CAR-T、双抗和新药试验会专门招 DLBCL。 |
| 滤泡性淋巴瘤 / Follicular lymphoma | 一种常见惰性 B 细胞淋巴瘤。 | 搜索时要和 DLBCL 分开，试验条件不同。 |
| 霍奇金淋巴瘤 / Hodgkin lymphoma | 与非霍奇金淋巴瘤不同的一大类淋巴瘤。 | 可以找 PD-1、CD30、复发难治相关试验。 |
| Relapsed / refractory | 复发或难治，指治疗后复发或对治疗反应不理想。 | 很多海外血液肿瘤试验会限定 R/R 患者。 |
| CAR-T | 一种细胞治疗方式，常见靶点包括 CD19 等。 | 可以找 CAR-T、cell therapy、CD19 相关试验。 |
| Bispecific antibody | 双特异性抗体，常见方向包括 CD20xCD3 等。 | 复发难治淋巴瘤中常见研究方向。 |
Recruitment status
常见招募状态
| Recruiting | 正在招募，可能仍可申请参加。 |
| Not yet recruiting | 尚未开始招募，可关注后续开放时间。 |
| Active, not recruiting | 试验仍在进行，但通常不再招新患者。 |
| Completed | 试验已经完成。 |
| Terminated | 试验提前终止。 |
| Unknown | 公开页面上的状态不明确或未及时更新。 |
Before contact
联系前准备资料
- 病理诊断报告
- 影像报告：CT / MRI / PET-CT
- 既往治疗记录
- 用药历史
- 基因检测报告
- 最近血液检查结果
- 出院小结
- 主治医生英文病情摘要，如果有
- 护照和签证情况，如果考虑出国
Filters
搜索时重点关注
- Recruiting / Not yet recruiting
- Location
- Age
- Phase
- Inclusion Criteria
- Exclusion Criteria
- Prior treatments
- Biomarker / mutation requirements
- ECOG performance status
- 是否接受 international patients
- 是否需要长期停留在试验所在地
- 费用、保险、翻译、住宿和陪护安排
Ask your doctor
可以带去问医生的问题
- 我的病理类型是否符合这个试验？
- 我之前用过的药会不会影响入组？
- 我是否需要做基因检测？
- 这个试验是几期？主要目的是什么？
- 参加试验会不会影响当前治疗？
- 如果去国外参加，风险和成本大概有哪些？
- 研究团队是否接受海外患者？
请将检索到的临床试验信息带给主治医生或肿瘤科医生讨论。本站不判断患者是否适合任何临床试验。